JP2003530839A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003530839A5 JP2003530839A5 JP2001576866A JP2001576866A JP2003530839A5 JP 2003530839 A5 JP2003530839 A5 JP 2003530839A5 JP 2001576866 A JP2001576866 A JP 2001576866A JP 2001576866 A JP2001576866 A JP 2001576866A JP 2003530839 A5 JP2003530839 A5 JP 2003530839A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- albumin fusion
- albumin
- protein according
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000009027 Albumins Human genes 0.000 description 38
- 108010088751 Albumins Proteins 0.000 description 38
- 108020001507 fusion proteins Proteins 0.000 description 28
- 102000037865 fusion proteins Human genes 0.000 description 28
- 102000006992 Interferon-alpha Human genes 0.000 description 14
- 108010047761 Interferon-alpha Proteins 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22935800P | 2000-04-12 | 2000-04-12 | |
| US60/229,358 | 2000-04-12 | ||
| US19938400P | 2000-04-25 | 2000-04-25 | |
| US60/199,384 | 2000-04-25 | ||
| US25693100P | 2000-12-21 | 2000-12-21 | |
| US60/256,931 | 2000-12-21 | ||
| PCT/US2001/012009 WO2001079271A1 (en) | 2000-04-12 | 2001-04-12 | Albumin fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011109620A Division JP2011217750A (ja) | 2000-04-12 | 2011-05-16 | アルブミン融合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003530839A JP2003530839A (ja) | 2003-10-21 |
| JP2003530839A5 true JP2003530839A5 (enExample) | 2008-05-29 |
Family
ID=27394014
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001577426A Pending JP2003531590A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
| JP2001576866A Pending JP2003530839A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
| JP2001576855A Pending JP2003530838A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
| JP2001577463A Pending JP2003530852A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
| JP2001575607A Pending JP2004506407A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
| JP2001577427A Pending JP2003530846A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
| JP2001577428A Pending JP2003530847A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
| JP2011109620A Pending JP2011217750A (ja) | 2000-04-12 | 2011-05-16 | アルブミン融合タンパク質 |
| JP2013216509A Pending JP2014057589A (ja) | 2000-04-12 | 2013-10-17 | アルブミン融合タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001577426A Pending JP2003531590A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001576855A Pending JP2003530838A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
| JP2001577463A Pending JP2003530852A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
| JP2001575607A Pending JP2004506407A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
| JP2001577427A Pending JP2003530846A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
| JP2001577428A Pending JP2003530847A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
| JP2011109620A Pending JP2011217750A (ja) | 2000-04-12 | 2011-05-16 | アルブミン融合タンパク質 |
| JP2013216509A Pending JP2014057589A (ja) | 2000-04-12 | 2013-10-17 | アルブミン融合タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (23) | US20040010134A1 (enExample) |
| EP (21) | EP2267026A1 (enExample) |
| JP (9) | JP2003531590A (enExample) |
| AU (7) | AU2001262942A1 (enExample) |
| BE (1) | BE2016C059I2 (enExample) |
| CA (8) | CA2405550A1 (enExample) |
| DK (2) | DK2236152T3 (enExample) |
| ES (2) | ES2529300T3 (enExample) |
| FR (1) | FR16C0043I2 (enExample) |
| WO (7) | WO2001079480A1 (enExample) |
Families Citing this family (665)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| WO2001034626A1 (en) * | 1999-11-05 | 2001-05-17 | Human Genome Sciences, Inc. | 28 human secreted proteins |
| WO2002016388A1 (en) * | 2000-08-18 | 2002-02-28 | Human Genome Sciences, Inc. | 21 human secreted proteins |
| US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP0892047A3 (de) * | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| US20030166107A1 (en) * | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20050181482A1 (en) * | 2004-02-12 | 2005-08-18 | Meade Harry M. | Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk |
| AU775422B2 (en) * | 1998-06-15 | 2004-07-29 | Gtc Biotherapeutics, Inc. | Erythropoietin analog-human serum albumin fusion |
| US20040199099A1 (en) * | 1998-07-10 | 2004-10-07 | Matson James R | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease |
| DE69926009D1 (de) | 1998-10-13 | 2005-08-04 | Univ Georgia Res Found | Stabilisierte bioaktive peptide und methoden zu ihrer identifikation, synthese und verwendung |
| US20030190740A1 (en) | 1998-10-13 | 2003-10-09 | The University Of Georgia Research Foundation, Inc | Stabilized bioactive peptides and methods of identification, synthesis, and use |
| EP2230303B1 (en) * | 1999-05-05 | 2013-01-16 | Phylogica Limited | Isolating biological modulators from biodiverse gene fragment libraries |
| US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| US7632803B2 (en) | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| US7592304B2 (en) | 1999-10-01 | 2009-09-22 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| CA2388822A1 (en) * | 1999-10-29 | 2001-05-10 | Human Genome Sciences, Inc. | 27 human secreted proteins |
| AU1578901A (en) * | 1999-11-05 | 2001-06-06 | Human Genome Sciences, Inc. | 24 human secreted proteins |
| JP2003520031A (ja) * | 1999-11-12 | 2003-07-02 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ２８個のヒト分泌タンパク質 |
| PT1234031T (pt) | 1999-11-30 | 2017-06-26 | Mayo Foundation | B7-h1, uma nova molécula imunoregulatória |
| WO2001045746A2 (en) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| US7534417B2 (en) | 2000-02-24 | 2009-05-19 | Agensys, Inc. | 103P2D6: tissue specific protein highly expressed in various cancers |
| US7291122B2 (en) * | 2000-03-24 | 2007-11-06 | Immunocept, L.L.C. | Hemofiltration methods for treatment of diseases in a mammal |
| CA2405550A1 (en) * | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
| CA2408664A1 (en) * | 2000-05-12 | 2001-11-15 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | F-box containing protein |
| US6787040B2 (en) * | 2000-05-16 | 2004-09-07 | Immunocept, L.L.C. | Method and system for colloid exchange therapy |
| AU2001274923A1 (en) * | 2000-05-23 | 2001-12-03 | Lexicon Genetics Incorporated | Novel human thrombospondin-like proteins and polynucleotides encoding the same |
| US6965018B2 (en) | 2000-06-06 | 2005-11-15 | Bristol-Myers Squibb Company | Antibodies directed to B7-related polypeptide, BSL-2 |
| JP2004500862A (ja) * | 2000-06-08 | 2004-01-15 | インサイト・ゲノミックス・インコーポレイテッド | 細胞内シグナル伝達タンパク質 |
| EP1294871A1 (en) * | 2000-06-21 | 2003-03-26 | Amgen, Inc. | Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof |
| AU2001232810A1 (en) * | 2000-08-18 | 2002-03-04 | Human Genome Sciences, Inc. | 23 human secreted proteins |
| AU2001229509A1 (en) * | 2000-08-18 | 2002-03-04 | Human Genome Sciences, Inc. | 11 human secreted proteins |
| AU2001232835A1 (en) * | 2000-08-28 | 2002-03-13 | Human Genome Sciences, Inc. | 18 human secreted proteins |
| CA2420192A1 (en) * | 2000-09-20 | 2002-03-28 | Human Genome Sciences, Inc. | 21 human secreted proteins |
| EP1330466A4 (en) * | 2000-09-29 | 2004-03-24 | Human Genome Sciences Inc | 24 HUMANE SECONDED PROTEINS |
| EP1325120A4 (en) * | 2000-10-12 | 2005-05-25 | Nuvelo Inc | NUCLEIC ACIDS AND POLYPEPTIDES |
| US6949371B2 (en) | 2000-10-20 | 2005-09-27 | Applera Corporation | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| US6531297B2 (en) * | 2000-10-20 | 2003-03-11 | Applera Corporation | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| FR2815964A1 (fr) * | 2000-10-30 | 2002-05-03 | Inst Nat Sante Rech Med | Proteine recepteur de la renine et/ou de la prorenine, acide nucleique codant pour ce recepteur et leur applications |
| US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| AU2002239229A1 (en) | 2000-12-05 | 2002-06-18 | Wisconsin Alumni Research Foundation | Receptor for b. anthracis toxin |
| DK1355942T3 (da) | 2000-12-07 | 2008-11-17 | Lilly Co Eli | GLP-1-fusionsproteiner |
| US20030148920A1 (en) * | 2000-12-27 | 2003-08-07 | Steven Rosen | Sulfatases and methods of use thereof |
| WO2002053737A1 (fr) * | 2000-12-28 | 2002-07-11 | Asahi Kasei Kabushiki Kaisha | Gene d'activation de nf-kb |
| CA2433469A1 (en) * | 2001-02-23 | 2002-09-06 | Human Genome Sciences, Inc. | 83 human secreted proteins |
| WO2002072138A1 (en) * | 2001-03-08 | 2002-09-19 | Hyseq, Inc. | Methods and materials relating to fibulin-like polypeptides and polynucleotides |
| US7736654B2 (en) | 2001-04-10 | 2010-06-15 | Agensys, Inc. | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
| US20060084794A1 (en) * | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7507413B2 (en) | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050244931A1 (en) * | 2001-04-12 | 2005-11-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20030119112A1 (en) | 2001-06-20 | 2003-06-26 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| EP1405077A2 (en) * | 2001-07-06 | 2004-04-07 | Geneprot, Inc. | Carcinoma-related peptides |
| US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| WO2003030821A2 (en) * | 2001-10-05 | 2003-04-17 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| DE10251673A1 (de) | 2001-11-09 | 2003-07-10 | Hoffmann La Roche | Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms |
| KR100406760B1 (ko) * | 2001-11-16 | 2003-11-21 | 신코엠 주식회사 | 반도체 메모리 장치 |
| DE60231057D1 (de) | 2001-12-17 | 2009-03-19 | Serono Lab | Chemokine mutanten, die als chemokine antagonisten wirken |
| US20040082761A1 (en) * | 2001-12-18 | 2004-04-29 | Duggan Brendan M. | Cell adhesion proteins |
| US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| KR101271635B1 (ko) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| AU2002364586A1 (en) * | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| US20060253913A1 (en) * | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
| CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7081446B2 (en) * | 2002-01-31 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Long-acting follicle stimulating hormone analogues and uses thereof |
| WO2003066824A2 (en) * | 2002-02-07 | 2003-08-14 | Aventis Behring Gmbh | Albumin-fused kunitz domain peptides |
| US20060241027A1 (en) * | 2002-02-07 | 2006-10-26 | Hans-Peter Hauser | Hiv inhibiting proteins |
| US20050222023A1 (en) * | 2002-02-07 | 2005-10-06 | Hans-Peter Hauser | Albumin-fused kunitz domain peptides |
| DE10205520A1 (de) * | 2002-02-08 | 2003-08-14 | Aventis Behring Gmbh | Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease |
| MXPA04008149A (es) * | 2002-02-21 | 2005-06-17 | Wyeth Corp | Proteinas que contienen dominios de folistatina. |
| EP1483580A4 (en) * | 2002-03-05 | 2006-10-11 | Merck & Co Inc | BIOMARKERS FOR THE EFFICACY OF APPETIZERS |
| US20030191056A1 (en) * | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| JP4585766B2 (ja) * | 2002-04-15 | 2010-11-24 | アメリカン ナショナル レッド クロス | 混合物中のリガンドおよび標的を検出する方法 |
| US20070015230A1 (en) * | 2002-04-15 | 2007-01-18 | Hammond David J | Identification and characterization of analytes from whole blood |
| AU2003234136A1 (en) | 2002-04-18 | 2003-11-03 | The General Hospital Corporation | Drg11-responsive (dragon) gene family |
| US7141381B2 (en) | 2002-04-25 | 2006-11-28 | Bristol-Myers Squibb Company | Human leucine-rich repeat-containing proteins specifically expressed in the nervous system |
| GB0210464D0 (en) * | 2002-05-08 | 2002-06-12 | Svanborg Catharina | Therapeutic treatment |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| PT1531850E (pt) * | 2002-06-07 | 2012-05-07 | Zymogenetics Inc | Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos |
| ATE528014T1 (de) | 2002-06-07 | 2011-10-15 | Dyax Corp | Polypeptid mit modifizierten kunitz domains |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| CN1241946C (zh) * | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
| CN101172091B (zh) * | 2007-09-25 | 2011-04-27 | 北京美福源生物医药科技有限公司 | 含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途 |
| KR100711145B1 (ko) * | 2002-07-03 | 2007-04-24 | (주)넥스젠 | 상피세포재생인자 및 인간 혈청 알부민을 포함하는 융합폴리펩타이드 |
| WO2004004649A2 (en) * | 2002-07-08 | 2004-01-15 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JPWO2004009626A1 (ja) * | 2002-07-22 | 2005-11-17 | アステラス製薬株式会社 | 慢性関節リウマチ関連新規遺伝子 |
| GB0217033D0 (en) | 2002-07-23 | 2002-08-28 | Delta Biotechnology Ltd | Gene and polypeptide sequences |
| AU2003271043A1 (en) * | 2002-08-07 | 2004-02-25 | Novozymes Biopharma Dk A/S | Albumin-fused ciliary neurotrophic factor |
| WO2004014315A2 (en) * | 2002-08-13 | 2004-02-19 | Arbios Systems, Inc. | Selective plasma exchange therapy |
| EP1542710B1 (en) | 2002-08-28 | 2012-09-26 | Dyax Corp. | Methods for preserving organs and tissues |
| EP1545611B1 (en) * | 2002-09-06 | 2016-11-09 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component c5 |
| US20050271660A1 (en) * | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| WO2004027064A2 (en) * | 2002-09-18 | 2004-04-01 | Centre Hospitalier De L'universite De Montreal (Chum) | Ghrh analogues |
| US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| ATE401346T1 (de) * | 2002-12-20 | 2008-08-15 | Geneos Oy | Asthma-empfindlichkeitsort |
| KR20050085881A (ko) * | 2002-12-26 | 2005-08-29 | 다케다 야쿠힌 고교 가부시키가이샤 | 신규 단백질 및 그 용도 |
| CA2513213C (en) * | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US8227212B2 (en) * | 2003-02-11 | 2012-07-24 | Shire Human Genetic Therapies, Inc. | Cell that expresses a sulfatase and a formylglycine generating enzyme |
| US7381410B2 (en) * | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| AU2004220459B2 (en) * | 2003-03-12 | 2010-08-05 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| WO2004082640A2 (en) * | 2003-03-19 | 2004-09-30 | New Century Pharmaceuticals, Inc. | Human serum albumin conjugates with therapeutic compounds |
| AU2004226162A1 (en) * | 2003-04-04 | 2004-10-14 | Universite De Lausanne | Peptabody for cancer treatment |
| AU2004229501B2 (en) | 2003-04-11 | 2011-08-18 | Medimmune, Llc | Recombinant IL-9 antibodies and uses thereof |
| WO2004094589A2 (en) * | 2003-04-18 | 2004-11-04 | Incyte Corporation | Secreted proteins |
| WO2004101620A2 (en) * | 2003-05-01 | 2004-11-25 | Compound Therapeutics, Inc. | Serum albumin scaffold-based proteins and uses thereof |
| US6987270B2 (en) | 2003-05-07 | 2006-01-17 | General Electric Company | Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes |
| US7517655B2 (en) * | 2003-06-30 | 2009-04-14 | Nihon University | Protein capable of deposition onto extracellular matrix |
| JP2008500005A (ja) | 2003-07-15 | 2008-01-10 | バロス リサーチ インスティテュート | 癌及び感染症の免疫療法のための組成物及び方法 |
| US8007805B2 (en) * | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
| GB0320877D0 (en) * | 2003-09-05 | 2003-10-08 | Celltech R&D Ltd | A protein involved in carcinoma |
| RS53073B (sr) | 2003-11-04 | 2014-04-30 | Novartis Vaccines And Diagnostics Inc. | Upotreba antagonističkih anti-cd40 monoklonska antitela |
| US20080292581A1 (en) * | 2003-12-03 | 2008-11-27 | Delta Biotechnology Limited | Interleukin-11 Fusion Proteins |
| CN100379762C (zh) * | 2003-12-08 | 2008-04-09 | 中国人民解放军军事医学科学院生物工程研究所 | 人血清白蛋白与白细胞介素2的融合蛋白及其编码基因 |
| US9050378B2 (en) | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
| WO2005058961A2 (en) | 2003-12-12 | 2005-06-30 | Amgen Inc. | Antibodies specific for human galanin, and uses thereof |
| GB0329722D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Modified plasmid and use thereof |
| GB0329681D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Gene expression technique |
| EP1712619A4 (en) * | 2003-12-24 | 2008-01-02 | Takeda Pharmaceutical | MEANS FOR PREVENTING / CUREING CANCER |
| SI1729795T1 (sl) * | 2004-02-09 | 2016-04-29 | Human Genome Sciences, Inc. | Albuminski fuzijski proteini |
| SE0400489D0 (sv) * | 2004-02-27 | 2004-02-27 | Biovitrum Ab | Therapeutic proteins |
| US20070166718A1 (en) * | 2004-03-03 | 2007-07-19 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases |
| JP2007528393A (ja) * | 2004-03-11 | 2007-10-11 | カイセラ バイオファーマシューティカルズ， インコーポレイテッド | 皮膚の状態および毛の状態を予防および処置するための組成物および方法 |
| US20050201959A1 (en) * | 2004-03-11 | 2005-09-15 | Vvii Newco 2003, Inc. | Methods and compositions for altering skin coloration |
| ATE492564T1 (de) | 2004-03-12 | 2011-01-15 | Vasgene Therapeutics Inc | Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum |
| EP1734991A4 (en) | 2004-04-14 | 2012-10-24 | Avirid Inc | COMPOSITIONS COMPRISING MODIFIED NUCLEASES DIRECTED AGAINST VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES |
| PT1745078E (pt) * | 2004-04-23 | 2009-09-17 | Conjuchem Biotechnologies Inc | Método para a purificação de conjugados de albumina |
| KR100599454B1 (ko) * | 2004-04-27 | 2006-07-12 | 재단법인서울대학교산학협력재단 | 종양 억제자로 작용하는 ａｉｍ3의 신규 용도 |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US8008020B2 (en) * | 2004-06-03 | 2011-08-30 | Vermillion, Inc. | Biomarkers for peripheral artery disease |
| CA2578709C (en) * | 2004-06-17 | 2010-06-15 | Virun, Inc. | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents |
| AU2005275062A1 (en) | 2004-07-14 | 2006-02-23 | University Of Utah Research Foundation | Netrin-related compositions and uses |
| CN101018874A (zh) * | 2004-08-13 | 2007-08-15 | 千年药品公司 | 用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法 |
| EP1793850A4 (en) | 2004-09-21 | 2010-06-30 | Medimmune Inc | ANTIBODIES TO THE METHOD AND METHOD FOR THE PRODUCTION OF VACCINES AGAINST THE RESPIRATORY SYNCYTIAL VIRUS |
| EP1799713B1 (en) | 2004-09-23 | 2014-11-05 | VasGene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| US20060078541A1 (en) * | 2004-10-01 | 2006-04-13 | Giles Brian C | Method and formula for stem cells' stimulation, targeting release, trafficking and homing |
| PT3428191T (pt) * | 2004-10-06 | 2024-12-30 | Mayo Found Medical Education & Res | B7-h1 e tratamento do carcinona de células renais |
| WO2006042197A2 (en) * | 2004-10-11 | 2006-04-20 | The Board Of Trustees Of The Leland Standford Junior University | Use of del-1 in hair, bone and cartilage regeneration |
| KR101310511B1 (ko) | 2004-10-25 | 2013-09-25 | 임뮨 시스템 키 리미티드 | 흉선-특이성 단백질 |
| KR100583350B1 (ko) * | 2004-11-03 | 2006-06-05 | (주)넥스젠 | Ｆａｓ-1 도메인을 함유하는 융합 단백질을 이용한상피세포재생인자의 생산 방법 |
| SI1809663T1 (sl) * | 2004-11-09 | 2009-02-28 | Ares Trading Sa | Postopek za äśiĺ äśenje fsh |
| JP5631533B2 (ja) | 2004-12-23 | 2014-11-26 | ノボザイムス バイオファーマ デーコー アクティーゼルスカブ | 遺伝子発現技術 |
| US20090196850A1 (en) | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| US20060178301A1 (en) * | 2005-02-04 | 2006-08-10 | Mathias Jurs | Albumin-fused ciliary neurotrophic factor |
| WO2006089133A2 (en) | 2005-02-15 | 2006-08-24 | Duke University | Anti-cd19 antibodies and uses in oncology |
| US20110230407A1 (en) * | 2005-03-14 | 2011-09-22 | Alexander Yuzhakov | Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma |
| JP2008537777A (ja) * | 2005-03-23 | 2008-09-25 | ワイス | Ｇｄｆ−８調節剤に対する免疫応答の検出 |
| BRPI0609449A2 (pt) * | 2005-03-23 | 2010-04-06 | Wyeth Corp | detecção de agentes de modulação de gdf-8 |
| ATE497975T1 (de) | 2005-04-18 | 2011-02-15 | Novo Nordisk As | Il-21-varianten |
| US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| PL1874821T3 (pl) | 2005-04-26 | 2013-09-30 | Trion Pharma Gmbh | Kombinacja przeciwciał i glikokortykoidów do leczenia raka |
| US9345745B2 (en) | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
| US9585932B2 (en) | 2005-04-29 | 2017-03-07 | Peter C. Dowling | Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders |
| WO2007052154A2 (en) | 2005-04-29 | 2007-05-10 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
| AU2006244445B2 (en) | 2005-05-05 | 2013-04-18 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
| JP2008546426A (ja) * | 2005-05-12 | 2008-12-25 | ザイモジェネティクス， インコーポレイテッド | Ｔ細胞を共刺激するためにｐＨＨＬＡ２を使用する方法 |
| EP3130350A1 (en) | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| WO2007014167A2 (en) * | 2005-07-22 | 2007-02-01 | Five Prime Therapeutics, Inc. | Compositions for and methods of treating epithelial diseases with growth factors |
| US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| PL1919503T3 (pl) | 2005-08-10 | 2015-04-30 | Macrogenics Inc | Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| HUE038947T2 (hu) | 2005-08-26 | 2018-12-28 | Ares Trading Sa | Eljárás glikozilált béta-interferon elõállítására |
| US7713715B2 (en) * | 2005-09-06 | 2010-05-11 | University Of Tennessee Research Foundation | Method for diagnosing infections |
| US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| US20070212703A1 (en) * | 2005-09-27 | 2007-09-13 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| US20090099031A1 (en) * | 2005-09-27 | 2009-04-16 | Stemmer Willem P | Genetic package and uses thereof |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| WO2007040437A1 (en) * | 2005-10-03 | 2007-04-12 | Astrazeneca Ab | Fusion proteins having a modulated half-life in plasma |
| US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| US8604175B2 (en) * | 2005-12-09 | 2013-12-10 | Ares Trading S.A. | Method for purifying FSH or a FSH mutant |
| MX2008007140A (es) * | 2005-12-09 | 2009-03-04 | Seattle Genetics Inc | Metodos para utilizar agentes de union a cd40. |
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| AU2006329215A1 (en) * | 2005-12-22 | 2007-06-28 | Conjuchem Biotechnologies Inc. | Process for the production of preformed conjugates of albumin and a therapeutic agent |
| US20100015642A1 (en) * | 2006-01-05 | 2010-01-21 | Kwon Eugene D | B7-h1 and survivin in cancer |
| US20090215084A1 (en) * | 2006-01-05 | 2009-08-27 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
| EP1989326A4 (en) | 2006-01-17 | 2009-09-30 | Health Research Inc | BIO-HETERODUPLEX TRACKING TEST |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| WO2007097961A1 (en) * | 2006-02-16 | 2007-08-30 | Massachusetts Eye & Ear Infirmary | Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage |
| US8389688B2 (en) | 2006-03-06 | 2013-03-05 | Aeres Biomedical, Ltd. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| EP2738178A1 (en) * | 2006-04-05 | 2014-06-04 | AbbVie Biotechnology Ltd | Antibody purification |
| DE602007007923D1 (de) * | 2006-04-11 | 2010-09-02 | Csl Behring Gmbh | Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide |
| WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
| EP2046367A4 (en) * | 2006-06-07 | 2009-11-11 | Human Genome Sciences Inc | ALBUM INFUSION PROTEINS |
| EP2032607B2 (en) | 2006-06-14 | 2017-02-22 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| EP1867660A1 (en) | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| AU2013202566C1 (en) * | 2006-06-14 | 2018-07-12 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| US9139611B2 (en) * | 2006-07-13 | 2015-09-22 | Novozymes Biopharma Dk A/S | Process for preparing particles of proteinaceous material |
| ES2371495T3 (es) | 2006-07-24 | 2012-01-03 | Biorexis Pharmaceutical Corporation | Proteínas de fusión de exendina. |
| EP2049661A4 (en) * | 2006-08-04 | 2012-07-04 | Pharmathene Inc | RECOMBINANT BUTYRYLCHOLINESTERASE WITH LONG HALF-LIFE |
| CN103230598A (zh) * | 2006-09-06 | 2013-08-07 | 费斯生物制药公司 | 融合肽治疗组合物 |
| WO2008030558A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
| US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| WO2008088422A2 (en) * | 2006-10-25 | 2008-07-24 | Amgen Inc. | Toxin peptide therapeutic agents |
| EP2091968A2 (en) | 2006-10-26 | 2009-08-26 | Novo Nordisk A/S | Il-21 variants |
| JP5588175B2 (ja) | 2006-11-07 | 2014-09-10 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｐｃｓｋ９のアンタゴニスト |
| CA2673085C (en) | 2006-12-12 | 2013-10-15 | Biorexis Pharmaceutical Corporation | Transferrin fusion protein libraries |
| EP2514767A1 (en) | 2006-12-19 | 2012-10-24 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
| EP2115004A2 (en) | 2006-12-19 | 2009-11-11 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
| EP1935430A1 (en) * | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
| EP3231440A1 (en) | 2006-12-22 | 2017-10-18 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
| CA2915168C (en) | 2007-01-30 | 2017-05-23 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| JP2010518039A (ja) * | 2007-02-12 | 2010-05-27 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | カザールタイプ・セリン・プロテアーゼ阻害剤の治療への応用 |
| EP2142217B1 (en) | 2007-03-27 | 2014-11-05 | Merck Sharp & Dohme Corp. | Method for detecting autoprocessed, secreted pcsk9 |
| BRPI0811466A2 (pt) | 2007-05-07 | 2014-10-14 | Medimmune Llc | Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica. |
| DK3072525T3 (en) | 2007-05-14 | 2018-04-30 | Astrazeneca Ab | PROCEDURES FOR REDUCING BASOFILE CELL LEVELS |
| EP2162540A2 (en) | 2007-05-22 | 2010-03-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| EP2514762B1 (en) | 2007-07-13 | 2015-04-08 | The Johns Hopkins University | B7-DC variants |
| AU2008275911A1 (en) * | 2007-07-19 | 2009-01-22 | Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University | Self- anchoring MEMS intrafascicular neural electrode |
| BRPI0815416A2 (pt) * | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
| SI2195023T1 (en) | 2007-08-29 | 2018-07-31 | Sanofi | Humanized anti-CXCR5 antibodies, their derivatives and their uses |
| JP2009055838A (ja) * | 2007-08-31 | 2009-03-19 | Nipro Corp | 融合タンパク質、該融合タンパク質に関連する遺伝子、ベクター、形質転換体及び抗炎症性医薬組成物 |
| KR101661770B1 (ko) * | 2007-09-21 | 2016-10-04 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함 |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| WO2009053358A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying fc-fusion proteins |
| JP2011500757A (ja) * | 2007-10-22 | 2011-01-06 | メルク セローノ ソシエテ アノニム | Ｆｃ含有タンパク質の精製方法 |
| US9308257B2 (en) | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| EP3211010A1 (en) | 2007-12-21 | 2017-08-30 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (il-4r) - 173 |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| WO2009097318A1 (en) * | 2008-01-28 | 2009-08-06 | Bristol-Myers Squibb Company | A fluorescence polarization binding assay for characterizing glucokinase ligands |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| WO2009111315A2 (en) * | 2008-02-29 | 2009-09-11 | Mayo Foundation For Medical Education And Research | Methods for reducing granulomatous inflammation |
| JP5020135B2 (ja) * | 2008-03-19 | 2012-09-05 | ソニーモバイルコミュニケーションズ， エービー | 携帯端末装置およびコンピュータプログラム |
| ES2563553T3 (es) | 2008-04-01 | 2016-03-15 | Novo Nordisk A/S | Conjugados de insulina-albúmina |
| WO2009124931A2 (en) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Amino acid sequences directed against the notch pathways and uses thereof |
| MX2010011957A (es) | 2008-05-02 | 2011-03-04 | Novartis Ag Star | Moleculas de union basadas en fibronectina mejoradas y usos de las mismas. |
| AU2013202564B2 (en) * | 2008-06-24 | 2015-09-17 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
| CN103739712B (zh) * | 2008-06-24 | 2016-10-05 | 德国杰特贝林生物制品有限公司 | 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 |
| JP2011526303A (ja) | 2008-06-27 | 2011-10-06 | デューク ユニバーシティ | エラスチン様ペプチドを含む治療剤 |
| CA2767331A1 (en) | 2008-07-10 | 2010-01-14 | Angion Biomedica Corp. | Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| EP2313436B1 (en) | 2008-07-22 | 2014-11-26 | Ablynx N.V. | Amino acid sequences directed against multitarget scavenger receptors and polypeptides |
| WO2010015608A1 (en) | 2008-08-05 | 2010-02-11 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
| CA2735006A1 (en) * | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| EP2927240A1 (en) | 2008-08-25 | 2015-10-07 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| CN102282172B (zh) | 2008-09-07 | 2014-02-19 | 台湾醣联生技医药股份有限公司 | 抗伸展的ⅰ型鞘糖脂抗体、其衍生物以及用途 |
| EP2358392B1 (en) | 2008-11-12 | 2019-01-09 | MedImmune, LLC | Antibody formulation |
| CN102282168A (zh) * | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| CN102282265B (zh) | 2008-11-28 | 2020-07-24 | 埃默里大学 | 用于治疗传染病和肿瘤的方法 |
| WO2010077634A1 (en) * | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2010068526A1 (en) | 2008-12-12 | 2010-06-17 | Merck Sharp & Dohme Corp. | Pcsk9 immunoassay |
| JP2013516389A (ja) | 2009-01-06 | 2013-05-13 | ダイアックス コーポレーション | カリクレイン阻害剤による粘膜炎治療 |
| UA103221C2 (uk) | 2009-01-16 | 2013-09-25 | Тева Фармасьютікал Індастріз Лтд. | Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини |
| WO2010087927A2 (en) | 2009-02-02 | 2010-08-05 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| US8703717B2 (en) * | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| WO2010091122A1 (en) * | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
| US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| KR101722961B1 (ko) | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| CA2755133A1 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Selective and potent peptide inhibitors of kv1.3 |
| CN102549012B (zh) | 2009-05-07 | 2015-07-01 | 诺维信生物制药丹麦公司 | 纯化白蛋白的方法 |
| EP2258398A1 (en) * | 2009-05-26 | 2010-12-08 | Araclón Biotech, S. L. | Albumin-amyloid peptide conjugates and uses thereof |
| WO2010138555A2 (en) * | 2009-05-26 | 2010-12-02 | University Of Florida Research Foundation, Inc. | Small peptide expression system in mammalian cells |
| AU2010258898B8 (en) * | 2009-06-08 | 2015-02-05 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| JP5883384B2 (ja) | 2009-08-13 | 2016-03-15 | ザ ジョンズ ホプキンス ユニバーシティー | 免疫機能を調節する方法 |
| CA2770609A1 (en) | 2009-08-20 | 2011-02-24 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| BR112012004094A2 (pt) | 2009-08-24 | 2016-03-08 | Amunix Operating Inc | composições de fator vii de coagulação e métodos para fazer e usar as mesmas |
| US9044580B2 (en) | 2009-08-24 | 2015-06-02 | Arsenal Medical, Inc. | In-situ forming foams with outer layer |
| US9173817B2 (en) | 2009-08-24 | 2015-11-03 | Arsenal Medical, Inc. | In situ forming hemostatic foam implants |
| US20110202016A1 (en) * | 2009-08-24 | 2011-08-18 | Arsenal Medical, Inc. | Systems and methods relating to polymer foams |
| US10420862B2 (en) | 2009-08-24 | 2019-09-24 | Aresenal AAA, LLC. | In-situ forming foams for treatment of aneurysms |
| US8451450B2 (en) * | 2009-09-14 | 2013-05-28 | Bio-Rad Laboratories, Inc. | Near real time optical phase conjugation |
| UY32917A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moléculas de unión a dll-4 |
| US20110172398A1 (en) | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| KR101808602B1 (ko) | 2009-10-07 | 2017-12-13 | 마크로제닉스, 인크. | 푸코실화 정도의 변경으로 인해 개선된 이펙터 기능을 나타내는 Ｆｃ 영역-함유 폴리펩티드, 그것의 사용 방법 |
| EP2493916B1 (en) * | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Lung tumor markers and methods of use thereof |
| MX2012004793A (es) | 2009-10-30 | 2012-07-20 | Novozymes Biopharma Dk As | Variantes de albumina. |
| WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| IN2012DN03824A (enExample) | 2009-10-30 | 2015-08-28 | Merck Sharp & Dohme | |
| US8802827B2 (en) | 2009-10-30 | 2014-08-12 | Merck Sharp & Dohme Corp. | AX1 PCSK9 antagonists |
| WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
| WO2011060528A1 (en) * | 2009-11-17 | 2011-05-26 | Universite De Montreal | Heteropeptides useful for reducing nonspecific adsorption |
| MX353233B (es) | 2009-12-06 | 2018-01-08 | Bioverativ Therapeutics Inc | Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos. |
| EP2826489A1 (en) | 2009-12-08 | 2015-01-21 | Teva Pharmaceutical Industries, Ltd. | BChE albumin fusions for the treatment of cocaine abuse |
| US8962807B2 (en) | 2009-12-14 | 2015-02-24 | Ablynx N.V. | Single variable domain antibodies against OX40L, constructs and therapeutic use |
| WO2011084145A2 (en) | 2009-12-21 | 2011-07-14 | Pharmathene, Inc. | Recombinant butyrylcholinesterases and truncates thereof |
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| TWI513466B (zh) | 2010-01-20 | 2015-12-21 | Boehringer Ingelheim Int | 抗凝血劑解毒劑 |
| US9211342B2 (en) | 2010-01-22 | 2015-12-15 | Novo Nordisk Healthcare Ag | Stable growth hormone compounds resistant to proteolytic degradation |
| MX345736B (es) | 2010-01-22 | 2017-02-14 | Novo Nordisk Healthcare Ag | Hormonas de crecimiento con eficacia in vivo prolongada. |
| WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| EP2547328B1 (en) * | 2010-02-11 | 2017-06-07 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Ccr7 ligand delivery and co-delivery in immunotherapy |
| WO2011107507A1 (en) | 2010-03-03 | 2011-09-09 | Boehringer Ingelheim International Gmbh | Biparatopic abeta binding polypeptides |
| EP2371857A1 (en) | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
| JP5969458B2 (ja) | 2010-04-09 | 2016-08-17 | アルブミディクス アクティーゼルスカブ | アルブミン誘導体及び変異体 |
| ES2659406T3 (es) | 2010-05-06 | 2018-03-15 | Novartis Ag | Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6) |
| US9290573B2 (en) | 2010-05-06 | 2016-03-22 | Novartis Ag | Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies |
| SG185354A1 (en) | 2010-05-20 | 2012-12-28 | Ablynx Nv | Biological materials related to her3 |
| CN103140237A (zh) | 2010-07-09 | 2013-06-05 | 比奥根艾迪克依蒙菲利亚公司 | 因子ix多肽及其使用方法 |
| US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
| WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| AU2011289579B2 (en) | 2010-08-10 | 2016-11-17 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| PL2606070T3 (pl) | 2010-08-20 | 2017-06-30 | Novartis Ag | Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3) |
| BR112013004776A2 (pt) | 2010-08-27 | 2017-09-19 | Stem Centrx Inc | moduladores de proteína notum e métodos de uso |
| US20120225081A1 (en) | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| CN103476429B (zh) | 2010-09-03 | 2016-08-24 | 施特姆森特克斯股份有限公司 | 新型调节剂及使用方法 |
| CA2885176C (en) | 2010-09-22 | 2018-10-23 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| EA024507B1 (ru) | 2010-09-28 | 2016-09-30 | Амилин Фармасьютикалс, Ллк | Хорошо растворимые лептины |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| US8892184B2 (en) | 2010-10-18 | 2014-11-18 | Siemens Medical Solutions Usa, Inc. | Systems and methods for reducing interference in a dual modality imaging system |
| US8853490B2 (en) * | 2010-10-26 | 2014-10-07 | Pioneer Hi Bred International Inc | Antifungal proteins and methods of use |
| WO2012059486A1 (en) | 2010-11-01 | 2012-05-10 | Novozymes Biopharma Dk A/S | Albumin variants |
| RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | Займворкс Инк. | ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ |
| KR101650995B1 (ko) | 2010-11-08 | 2016-08-25 | 노파르티스 아게 | Ｃｘｃｒ２ 결합 폴리펩티드 |
| US9095606B1 (en) | 2010-11-13 | 2015-08-04 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
| US9066974B1 (en) | 2010-11-13 | 2015-06-30 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
| US20130245233A1 (en) | 2010-11-24 | 2013-09-19 | Ming Lei | Multispecific Molecules |
| US20140302034A1 (en) | 2010-12-08 | 2014-10-09 | Stem Centrx, Inc. | Novel modulators and methods of use |
| WO2012091138A1 (ja) | 2010-12-28 | 2012-07-05 | 大日本住友製薬株式会社 | アルツハイマー病の診断薬及び診断方法 |
| US20120171195A1 (en) | 2011-01-03 | 2012-07-05 | Ravindranath Mepur H | Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use |
| IL269565B2 (en) | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| US20140105898A1 (en) | 2011-02-28 | 2014-04-17 | Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo | Apoptosis-inducing molecules and uses therefor |
| AU2012222833B2 (en) | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
| JP6109081B2 (ja) | 2011-03-09 | 2017-04-05 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 人工表面との接触を含む医学的手技に伴う投与のためのｆｘｉｉ阻害剤 |
| EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| EP2686014A1 (en) | 2011-03-16 | 2014-01-22 | Sanofi | Uses of a dual v region antibody-like protein |
| SG10201601789TA (en) | 2011-03-16 | 2016-04-28 | Amgen Inc | Potent And Selective Inhibitors Of Nav1.3 And Nav1.7 |
| US9340584B2 (en) | 2011-03-29 | 2016-05-17 | The General Hospital Corporation | Engineered thioredoxin-like fold proteins |
| PH12013501924A1 (en) | 2011-03-30 | 2017-10-25 | Boehringer Ingelheim Int | Anticoagulant antidotes |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US20130078247A1 (en) | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US9409987B2 (en) | 2011-04-15 | 2016-08-09 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| EP2515112B1 (en) * | 2011-04-22 | 2015-08-12 | Sysmex Corporation | Method for electrochemically detecting analyte |
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| CA2830660A1 (en) | 2011-05-05 | 2012-11-08 | Novozymes Biopharma Dk A/S | Albumin variants |
| WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
| US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
| DK2717898T3 (en) | 2011-06-10 | 2019-03-25 | Bioverativ Therapeutics Inc | COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF |
| WO2012172495A1 (en) | 2011-06-14 | 2012-12-20 | Novartis Ag | Compositions and methods for antibodies targeting tem8 |
| US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
| UA124083C2 (uk) | 2011-06-28 | 2021-07-21 | ІНГІБРЕКС, Інк. | Злитий серпіновий поліпептид і спосіб його застосування |
| MX2014000031A (es) | 2011-07-01 | 2014-07-09 | Bayer Ip Gmbh | Polipeptidos de fusion de relaxina y usos de los mismos. |
| CN103649111B (zh) | 2011-07-05 | 2018-03-13 | 阿尔布梅迪克斯医疗公司 | 白蛋白制剂和用途 |
| DK2729160T3 (da) | 2011-07-08 | 2019-07-01 | Aegerion Pharmaceuticals Inc | Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet |
| MX2014000316A (es) | 2011-07-08 | 2014-02-19 | Bayer Ip Gmbh | Proteinas de fusion liberadoras de relaxina y usos de las mismas. |
| US9353172B2 (en) * | 2011-07-18 | 2016-05-31 | Arts Biologics A/S | Long acting biologically active luteinizing hormone (LH) compound |
| RS66465B1 (sr) | 2011-07-22 | 2025-02-28 | Csl Behring Gmbh | Inhibitorna monoklonska antitela protiv faktora xii/xiia i njihove upotrebe |
| US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| AU2012332587B2 (en) | 2011-11-01 | 2017-02-23 | Bionomics, Inc. | Antibodies and methods of treating cancer |
| AU2012332593B2 (en) | 2011-11-01 | 2016-11-17 | Bionomics, Inc. | Anti-GPR49 antibodies |
| US9220774B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Methods of treating cancer by administering anti-GPR49 antibodies |
| US8993831B2 (en) * | 2011-11-01 | 2015-03-31 | Arsenal Medical, Inc. | Foam and delivery system for treatment of postpartum hemorrhage |
| WO2013067055A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
| KR102052774B1 (ko) | 2011-11-04 | 2019-12-04 | 자임워크스 인코포레이티드 | Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계 |
| MX2014005411A (es) | 2011-11-04 | 2015-02-12 | Novartis Ag | Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6). |
| US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
| EP2788382A2 (en) | 2011-12-05 | 2014-10-15 | Novartis AG | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
| AU2012349735B2 (en) | 2011-12-05 | 2016-05-19 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| CA2859493A1 (en) | 2011-12-21 | 2013-06-27 | Novartis Ag | Compositions and methods for antibodies targeting factor p |
| EP2793935B1 (en) | 2011-12-22 | 2016-05-25 | CSL Behring GmbH | Use of c1-inhibitor for the treatment of secondary edema of the central nervous system |
| US20130177574A1 (en) | 2012-01-11 | 2013-07-11 | Paul I. Terasaki Foundation Laboratory | ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE |
| US10800847B2 (en) | 2012-01-11 | 2020-10-13 | Dr. Mepur Ravindranath | Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use |
| EA035323B1 (ru) | 2012-01-12 | 2020-05-28 | Биовератив Терапьютикс Инк. | Полипептиды химерного фактора viii и их применение |
| EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| CN104271148A (zh) | 2012-02-15 | 2015-01-07 | 洛桑聚合联合学院 | 红细胞结合性治疗剂 |
| ES2651523T3 (es) * | 2012-02-15 | 2018-01-26 | Csl Behring Gmbh | Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada |
| LT2822577T (lt) | 2012-02-15 | 2019-03-25 | Bioverativ Therapeutics Inc. | Rekombinantiniai faktoriaus viii baltymai |
| HRP20221531T1 (hr) | 2012-02-15 | 2023-02-17 | Bioverativ Therapeutics Inc. | Pripravci faktora viii i postupci dobivanja i korištenja istih |
| ES2812849T3 (es) | 2012-02-24 | 2021-03-18 | Abbvie Stemcentrx Llc | Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos |
| UA115781C2 (uk) | 2012-02-27 | 2017-12-26 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cx3cr1-зв'язуючий поліпептид |
| DK2825556T3 (en) | 2012-03-16 | 2018-04-16 | Albumedix As | albumin Variants |
| GB201204868D0 (en) * | 2012-03-20 | 2012-05-02 | San Raffaele Centro Fond | Peptides |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| EP2830646B1 (en) | 2012-03-27 | 2018-03-07 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| AU2013251310B2 (en) * | 2012-04-27 | 2018-02-15 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| WO2013166290A1 (en) | 2012-05-04 | 2013-11-07 | Abbvie Biotherapeutics Inc. | P21 biomarker assay |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| CA2872540A1 (en) | 2012-05-10 | 2013-11-14 | Zymeworks Inc. | Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain |
| WO2013177386A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Biotherapeutics Inc. | Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| ES2694201T3 (es) | 2012-05-30 | 2018-12-19 | Bayer Cropscience Ag | Composición que comprende un agente de control biológico y trifloxiestrobina |
| CN104507310B (zh) | 2012-05-30 | 2018-04-13 | 拜尔农作物科学股份公司 | 包括生物防治剂和杀昆虫剂的组合物 |
| EP2854548B1 (en) | 2012-05-30 | 2018-08-01 | Bayer Cropscience AG | Composition comprising a biological control agent and a fungicide selected from metalaxyl and metalaxyl-m |
| WO2013178663A1 (en) | 2012-05-30 | 2013-12-05 | Bayer Cropscience Ag | Compositions comprising a biological control agent and an insecticide |
| NZ742941A (en) | 2012-05-30 | 2019-09-27 | Bayer Cropscience Ag | Composition comprising a biological control agent and a fungicide selected from inhibitors of the mitosis and cell division or compounds having a multi-site action |
| AU2013269661B2 (en) | 2012-05-30 | 2016-10-27 | Bayer Cropscience Ag | Compositions comprising a biological control agent and an insecticide |
| EP2854552B1 (en) | 2012-05-30 | 2019-05-08 | Bayer Cropscience AG | Composition comprising a biological control agent and a fungicide selected from inhibitors of amino acid or protein biosynthesis, inhibitors of atp production and inhibitors of the cell wall synthesis |
| AR091196A1 (es) | 2012-05-30 | 2015-01-21 | Bayer Cropscience Ag | Composicion que comprende un agente de control biologico y un fungicida |
| JP6285423B2 (ja) | 2012-05-30 | 2018-02-28 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 生物農薬および殺虫剤を含む組成物 |
| CN104470359B (zh) | 2012-05-30 | 2017-05-24 | 拜尔农作物科学股份公司 | 包括一种生物防治剂和一种杀虫剂的组合物 |
| BR122019010584B1 (pt) | 2012-05-30 | 2020-06-30 | Bayer Cropscience Ag. | composição que compreende um agente de controle biológico e um fungicida, seus usos, semente resistente a patógeno, método para reduzir os danos totais em plantas e em partes de plantas, e kit de partes |
| EP3281526A1 (en) | 2012-05-30 | 2018-02-14 | Bayer CropScience Aktiengesellschaft | Composition comprising a biological control agent and a fungicide |
| AU2013270683A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Chimeric clotting factors |
| CA2875246A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Procoagulant compounds |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
| US10656156B2 (en) | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
| US10138291B2 (en) | 2012-07-11 | 2018-11-27 | Bioverativ Therapeutics Inc. | Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof |
| IN2015DN01115A (enExample) | 2012-07-13 | 2015-06-26 | Zymeworks Inc | |
| US20150202287A1 (en) | 2012-08-30 | 2015-07-23 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| BR112015004467A2 (pt) | 2012-09-02 | 2017-03-21 | Abbvie Inc | método para controlar a heterogeneidade de proteínas |
| CA2888806A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
| KR20150082422A (ko) | 2012-11-08 | 2015-07-15 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 변이체 |
| UA128182C2 (uk) | 2012-11-13 | 2024-05-01 | Біонтех Аґ | Агенти для лікування експресуючих клаудин ракових захворювань |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| WO2014084859A1 (en) | 2012-11-30 | 2014-06-05 | Novartis Ag | Molecules and methods for modulating tmem16a activities |
| HRP20210517T1 (hr) | 2012-12-05 | 2021-05-14 | Novartis Ag | Pripravci i postupci za protutijela usmjerena na epo |
| US20160067347A1 (en) | 2012-12-20 | 2016-03-10 | Amgen Inc. | Apj receptor agonists and uses thereof |
| WO2014113359A1 (en) | 2013-01-15 | 2014-07-24 | Teva Pharmaceutical Industries Ltd. | Formulations of albu-bche, preparation and uses thereof |
| KR101503907B1 (ko) * | 2013-01-17 | 2015-03-20 | 서울대학교산학협력단 | 흉막폐렴균과 마이코플라즈마 하이오뉴모니아 감염 질환 예방을 위한 재조합 단백질 백신 |
| US9828415B2 (en) | 2013-01-30 | 2017-11-28 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| US20150373973A1 (en) | 2013-02-11 | 2015-12-31 | Bayer Cropscience Lp | Compositions comprising gougerotin and a biological control agent |
| LT2956477T (lt) | 2013-02-15 | 2021-02-10 | Bioverativ Therapeutics Inc. | Optimizuotas faktoriaus viii genas |
| CN105007722A (zh) | 2013-02-16 | 2015-10-28 | 诺维信生物制药丹麦公司 | 药代动力学动物模型 |
| WO2014131865A1 (en) | 2013-02-28 | 2014-09-04 | Csl Behring Gmbh | Therapeutic agent for amniotic fluid embolism |
| USRE48805E1 (en) | 2013-03-06 | 2021-11-02 | Vision Global Holdings Ltd. | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein |
| US9255262B2 (en) * | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
| US10286047B2 (en) | 2013-03-08 | 2019-05-14 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
| US10981961B2 (en) | 2013-03-11 | 2021-04-20 | University Of Florida Research Foundation, Incorporated | Delivery of card protein as therapy for occular inflammation |
| CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US10344060B2 (en) | 2013-03-12 | 2019-07-09 | Amgen Inc. | Potent and selective inhibitors of Nav1.7 |
| WO2014165093A2 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
| US20160024181A1 (en) * | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014159239A2 (en) | 2013-03-14 | 2014-10-02 | Novartis Ag | Antibodies against notch 3 |
| US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EA037906B1 (ru) | 2013-03-15 | 2021-06-04 | Биовератив Терапьютикс Инк. | Препараты полипептида фактора ix |
| WO2014160958A1 (en) | 2013-03-29 | 2014-10-02 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| CN105120887A (zh) | 2013-04-05 | 2015-12-02 | 诺和诺德保健股份有限公司 | 生长激素化合物制剂 |
| DK2796145T3 (da) | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
| AR096601A1 (es) | 2013-06-21 | 2016-01-20 | Novartis Ag | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso |
| US9562101B2 (en) | 2013-06-21 | 2017-02-07 | Novartis Ag | Lectin-like oxidized LDL receptor 1 antibodies and methods of use |
| PL3013366T3 (pl) | 2013-06-28 | 2022-01-17 | Csl Behring Gmbh | Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1 |
| WO2014210558A1 (en) | 2013-06-28 | 2014-12-31 | Biogen Idec Ma Inc. | Thrombin cleavable linker with xten and its uses thereof |
| CN104342420B (zh) * | 2013-07-30 | 2017-09-15 | 惠觅宙 | 一种重组长效人透明质酸酶、其编码基因、生产方法及应用 |
| EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
| US20160311885A1 (en) | 2013-08-14 | 2016-10-27 | Biogen Ma Inc. | Recombinant factor viii proteins |
| CA2920835A1 (en) | 2013-08-20 | 2015-02-26 | Anutra Medical, Inc. | Syringe fill system and method |
| PE20160674A1 (es) | 2013-08-28 | 2016-07-21 | Stemcentrx Inc | Metodos de conjugacion de anticuerpos especificos de sitio y composiciones |
| EP3338793A1 (en) | 2013-08-28 | 2018-06-27 | AbbVie Stemcentrx LLC | Novel sez6 modulators and methods of use |
| HUE057005T2 (hu) | 2013-09-25 | 2022-04-28 | Bioverativ Therapeutics Inc | Oszlopon történõ vírusinaktiváló eljárások |
| CN103468662A (zh) * | 2013-09-29 | 2013-12-25 | 惠觅宙 | 一种重组人透明质酸酶、其生产纯化方法、制剂及使用方法与应用 |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| US10259875B2 (en) | 2013-10-01 | 2019-04-16 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of BIM |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| WO2015057403A2 (en) * | 2013-10-17 | 2015-04-23 | Tarix Pharmaceuticals Ltd. | Compositions and methods for treatment of inflammatory bowel disease |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| HRP20192080T1 (hr) | 2013-10-31 | 2020-02-07 | Resolve Therapeutics, Llc | Terapeutske fuzije nukleaza-albumine i postupci |
| CN105992770B (zh) | 2013-11-01 | 2021-06-25 | 奥斯陆大学 | 白蛋白的变体及其用途 |
| WO2015070014A1 (en) | 2013-11-08 | 2015-05-14 | Biogen Idec Ma Inc. | Procoagulant fusion compound |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| EP3091999B2 (en) | 2014-01-09 | 2025-05-07 | Hadasit Medical Research Services and Development Ltd. | Improved cell compositions and methods for cancer therapy |
| DK3091997T5 (da) | 2014-01-10 | 2024-10-14 | Bioverativ Therapeutics Inc | Kimære faktor viii-proteiner og anvendelser deraf |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| LT3107563T (lt) | 2014-02-21 | 2021-07-12 | Ecole Polytechnique Fédérale De Lausanne (Epfl) Epfl-Tto | Gliko-nukreipiantys terapiniai agenai |
| EP4050020A1 (en) | 2014-03-11 | 2022-08-31 | University of Florida Research Foundation, Inc. | Aav-expressed m013 protein as an anti-inflammatroy therapeutic for use in a method of treating inflammatory ocular disease |
| US20170107294A1 (en) * | 2014-03-21 | 2017-04-20 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
| WO2015160618A1 (en) | 2014-04-16 | 2015-10-22 | Bayer Cropscience Lp | Compositions comprising ningnanmycin and a biological control agent |
| WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
| MX2016014306A (es) | 2014-05-02 | 2017-06-12 | Cerenis Therapeutics Holding Sa | Marcadores para terapia con lipoproteinas de alta densidad (hdl). |
| WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
| CN105198999A (zh) * | 2014-05-27 | 2015-12-30 | 上海生物制品研究所有限责任公司 | 一种融合蛋白、其制备方法及其应用 |
| USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
| USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
| USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
| AU2015274574B2 (en) | 2014-06-10 | 2019-10-10 | Amgen Inc. | Apelin polypeptides |
| DK3157548T3 (da) | 2014-06-18 | 2021-09-06 | Csl Behring Gmbh | Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom |
| WO2015198199A1 (en) | 2014-06-23 | 2015-12-30 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof. |
| WO2015197446A1 (en) | 2014-06-24 | 2015-12-30 | Novo Nordisk A/S | Mic-1 fusion proteins and uses thereof |
| EP3160478A4 (en) | 2014-06-30 | 2018-05-16 | Bioverativ Therapeutics Inc. | Optimized factor ix gene |
| US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
| JP6704358B2 (ja) | 2014-07-30 | 2020-06-03 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 代謝障害を治療するための組成物および使用方法 |
| WO2016020882A2 (en) | 2014-08-07 | 2016-02-11 | Novartis Ag | Angiopoetin-like 4 (angptl4) antibodies and methods of use |
| SG10201805646WA (en) | 2014-08-07 | 2018-08-30 | Novartis Ag | Angiopoietin-like 4 antibodies and methods of use |
| CN106714818B (zh) | 2014-08-22 | 2020-04-21 | 成功大学 | 去整合蛋白变异体及其医药用途 |
| UA121316C2 (uk) | 2014-09-17 | 2020-05-12 | Байєр Кропсайєнс Лп | Композиція для посилення росту і/або сприяння життєздатності рослин, що містить рекомбінантні клітини представника сімейства bacillus cereus і інший агент біологічної боротьби |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| SG11201701803XA (en) | 2014-09-26 | 2017-04-27 | Bayer Pharma AG | Stabilized adrenomedullin derivatives and use thereof |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| EP3207130B1 (en) | 2014-10-14 | 2019-08-07 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| ES2799503T3 (es) | 2014-10-31 | 2020-12-18 | Ngm Biopharmaceuticals Inc | Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
| JP6798993B2 (ja) * | 2014-12-23 | 2020-12-09 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン | ボツリヌス毒素プレフィルド容器 |
| EP3277725B1 (en) * | 2015-03-30 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| JP2016204292A (ja) * | 2015-04-21 | 2016-12-08 | 国立大学法人 熊本大学 | Ｂｍｐ７変異体とアルブミンとの融合体、及び該融合体を含む腎疾患治療剤 |
| CA2979973A1 (en) * | 2015-04-29 | 2016-11-03 | Mediolanum Farmaceutici S.P.A. | A soluble chimeric interleukin-10 receptor and therapeutic use thereof |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| WO2016195723A1 (en) * | 2015-06-03 | 2016-12-08 | Beller Pharmaceuticals LLC | Methods of treatment for conditions mediated by substance p |
| CA2982237A1 (en) | 2015-06-05 | 2016-12-08 | Novartis Ag | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor |
| GB2556531A (en) * | 2015-06-11 | 2018-05-30 | Attwill Medical Solutions Inc | Medical devices, systems, and methods utilizing antithrombin-heparin compositions |
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| JP2018522030A (ja) * | 2015-07-30 | 2018-08-09 | エンドール テクノロジーズ, エス.エレ.Endor Technologies, S.L. | 膵癌又は大腸癌の治療用コロニー刺激因子 |
| KR102728071B1 (ko) | 2015-08-03 | 2024-11-11 | 노파르티스 아게 | Fgf21-연관 장애를 치료하는 방법 |
| MX2018001497A (es) | 2015-08-03 | 2018-05-15 | Bioverativ Therapeutics Inc | Proteinas de fusion de factor ix y metodos para producirlas y usarlas. |
| EP3332012A4 (en) | 2015-08-06 | 2019-01-16 | The Trustees of The University of Pennsylvania | GLP-1 AND USE THEREOF IN COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES |
| EP3337816B1 (en) | 2015-08-20 | 2024-02-14 | Albumedix Ltd | Albumin variants and conjugates |
| PT3348635T (pt) | 2015-09-08 | 2021-03-15 | Japan Chem Res | Novo mutante de albumina do soro humano |
| RS61763B1 (sr) | 2015-09-09 | 2021-05-31 | Novartis Ag | Antitela koja vezuju timusni stromalni limfopoetin (tslp) i metode za korišćenje antitela |
| MY186352A (en) | 2015-09-09 | 2021-07-15 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies |
| CN117659160A (zh) * | 2015-09-11 | 2024-03-08 | 小利兰·斯坦福大学托管委员会 | 生物相关正交细胞因子/受体对 |
| US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
| MA54648A (fr) | 2015-12-04 | 2021-11-10 | Boehringer Ingelheim Int | Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales |
| CN116077648A (zh) | 2015-12-11 | 2023-05-09 | 武田药品工业株式会社 | 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途 |
| UY37030A (es) | 2015-12-18 | 2017-07-31 | Novartis Ag | Anticuerpos dirigidos a cd32b y métodos de uso de los mismos |
| WO2017109706A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| BR112018014150A2 (en) | 2016-01-11 | 2018-12-11 | Novartis Ag | immunostimulating humanized monoclonal antibodies to human interleukin-2, and fusion proteins thereof |
| WO2017125897A1 (en) | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
| PL3411478T3 (pl) | 2016-02-01 | 2022-10-03 | Bioverativ Therapeutics Inc. | Geny zoptymalizowanego czynnika VIII |
| JP2017165713A (ja) * | 2016-03-14 | 2017-09-21 | Ｊｃｒファーマ株式会社 | 血清アルブミン−２０ｋ成長ホルモン融合タンパク質 |
| CN108697799A (zh) | 2016-03-22 | 2018-10-23 | 生态学有限公司 | 抗lgr5单克隆抗体的施用 |
| JP7021099B2 (ja) | 2016-03-31 | 2022-02-18 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 結合タンパク質及びその使用方法 |
| KR20230136687A (ko) | 2016-04-06 | 2023-09-26 | 시에스엘 리미티드 | 죽상동맥경화증의 치료 방법 |
| JP7138567B2 (ja) | 2016-04-27 | 2022-09-16 | ノバルティス アーゲー | 成長分化因子１５に対する抗体およびそれらの使用 |
| MA55697A (fr) | 2016-05-18 | 2022-02-23 | Boehringer Ingelheim Int | Molécules d'anticorps pour le traitement du cancer |
| PE20190117A1 (es) | 2016-05-24 | 2019-01-16 | Novo Nordisk As | Compuestos de mic-1 y usos de estos |
| CN110381988A (zh) | 2016-06-15 | 2019-10-25 | 诺华股份有限公司 | 使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法 |
| EP3481416B1 (en) * | 2016-07-08 | 2020-09-09 | CSL Behring Lengnau AG | Subcutaneous administration of long-acting factor ix in humans |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| EP3493832A1 (en) | 2016-08-05 | 2019-06-12 | CSL Behring GmbH | Pharmaceutical formulations of c1 esterase inhibitor |
| EP3504648A1 (en) | 2016-08-23 | 2019-07-03 | CSL Behring GmbH | Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| JP2020500306A (ja) | 2016-11-04 | 2020-01-09 | オーフス ウニベルシテット | 新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療 |
| US11324804B2 (en) * | 2016-11-18 | 2022-05-10 | Sepsia Therapeutics, S.L. | Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes |
| WO2018096396A1 (en) | 2016-11-22 | 2018-05-31 | University Of Oslo | Albumin variants and uses thereof |
| BR112019011198A2 (pt) | 2016-12-02 | 2019-12-17 | Bioverativ Therapeutics Inc | métodos de indução de tolerância imune a fatores de coagulação |
| WO2018102743A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| MA47163A (fr) | 2016-12-16 | 2019-11-06 | Biogen Ma Inc | Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| GB2572918B (en) | 2016-12-23 | 2023-02-15 | Harvard College | Gene editing of PCSK9 |
| AU2017383232B2 (en) | 2016-12-23 | 2024-09-12 | Novartis Ag | Factor XI antibodies and methods of use |
| US20200231701A1 (en) | 2016-12-23 | 2020-07-23 | Novartis Ag | Methods of treatment with anti-factor xi/xia antibodies |
| WO2018132768A1 (en) | 2017-01-13 | 2018-07-19 | Sanna Pietro P | Methods and compositions for treating hpa hyperactivity |
| EA201991768A1 (ru) | 2017-01-31 | 2020-01-22 | Байоверетив Терапьютикс Инк. | Слитые белки на основе фактора ix и способы их получения и пути применения |
| JP6991246B2 (ja) | 2017-02-08 | 2022-02-03 | ノバルティス アーゲー | Ｆｇｆ２１模倣抗体及びその使用 |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| WO2018193033A1 (en) | 2017-04-20 | 2018-10-25 | Novo Nordisk A/S | Methods of purification of albumin fusion proteins |
| TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| IL322309A (en) | 2017-05-24 | 2025-09-01 | Novartis Ag | IL2 antibody grafted proteins and methods of use in cancer treatment |
| US11033636B2 (en) | 2017-05-31 | 2021-06-15 | Boehringer Ingelheim International Gmbh | Polypeptides antagonizing Wnt signaling in tumor cells |
| US11253579B2 (en) | 2017-06-16 | 2022-02-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| CN110799209A (zh) | 2017-06-29 | 2020-02-14 | 康诺贝林伦瑙有限公司 | 用于预防性治疗血友病的包含因子ix和人白蛋白的融合蛋白的21天给药方案及其方法 |
| JP7504025B2 (ja) | 2017-08-04 | 2024-06-21 | アムジエン・インコーポレーテツド | Ｃｙｓ－ｍａｂのコンジュゲーション方法 |
| JP7374883B2 (ja) | 2017-08-09 | 2023-11-07 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子およびその使用 |
| EP3684811A2 (en) | 2017-08-17 | 2020-07-29 | Massachusetts Institute of Technology | Multiple specificity binders of cxc chemokines and uses thereof |
| AU2018334213B2 (en) | 2017-09-15 | 2025-04-17 | Cedars-Sinai Medical Center | Methods for improving organ function in organ transplant patients |
| CN111247165B (zh) | 2017-10-18 | 2023-11-10 | Csl有限公司 | 人血清白蛋白变体及其应用 |
| US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| BR112020011240A2 (pt) | 2017-12-15 | 2020-11-24 | Csl Limited | uso de um inibidor de fxiia no tratamento de fibrose renal e/ou doença renal crônica |
| WO2019129054A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
| CN117050184A (zh) | 2017-12-28 | 2023-11-14 | 南京传奇生物科技有限公司 | 针对tigit的单域抗体和其变体 |
| US11246908B2 (en) * | 2018-01-10 | 2022-02-15 | The Johns Hopkins University | Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof |
| JP7366908B2 (ja) | 2018-01-15 | 2023-10-23 | ナンジン レジェンド バイオテック カンパニー，リミテッド | Ｐｄ－１に対する単一ドメイン抗体及びその変異体 |
| WO2019152692A1 (en) | 2018-02-01 | 2019-08-08 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing factor viii |
| HUE062829T2 (hu) * | 2018-03-13 | 2023-12-28 | Sepsia Therapeutics S L | Bakteriális összetevõt kötõ peptidek fertõzõ betegségek és kapcsolódó gyulladásos folyamatok kezelésére |
| IL277049B2 (en) | 2018-03-13 | 2024-02-01 | Zymeworks Bc Inc | Conjugates of biparatopic anti-HER2 antibody and drug and methods of use |
| US11359000B2 (en) | 2018-03-28 | 2022-06-14 | Bristol-Myers Squibb Company | Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use |
| AU2019241350B2 (en) | 2018-03-30 | 2025-10-02 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
| KR102119197B1 (ko) * | 2018-04-23 | 2020-06-05 | 주식회사 엘베이스 | 세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물 |
| EA202092723A1 (ru) | 2018-05-09 | 2021-04-09 | Зе Юниверсити Оф Чикаго | Композиции и способы, касающиеся иммунной толерантности |
| MX2020012252A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina 12 activables y metodos de uso de los mismos. |
| CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
| RS66972B1 (sr) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc | Metode lečenja hemofilije a |
| EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| TWI848951B (zh) | 2018-06-01 | 2024-07-21 | 瑞士商諾華公司 | 針對ｂｃｍａ之結合分子及其用途 |
| KR20210022004A (ko) | 2018-06-18 | 2021-03-02 | 안위타 바이오사이언시스, 인코포레이티드 | 항-메소텔린 작제물 및 이의 용도 |
| KR20210027426A (ko) | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf21 제제 |
| CN119955796A (zh) | 2018-08-09 | 2025-05-09 | 比奥维拉迪维治疗股份有限公司 | 核酸分子及其用于非病毒基因疗法的用途 |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| RS66543B1 (sr) | 2018-08-31 | 2025-03-31 | Regeneron Pharma | Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela |
| JP2022500427A (ja) * | 2018-09-17 | 2022-01-04 | 国立大学法人京都大学 | 肝傷害又は肝不全の処置のための抗ｃ５剤の投与 |
| KR20250154552A (ko) | 2018-09-27 | 2025-10-28 | 실리오 디벨럽먼트, 인크. | 마스킹된 사이토카인 폴리펩타이드 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| WO2020092839A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| GB201818477D0 (en) | 2018-11-13 | 2018-12-26 | Emstopa Ltd | Tissue plasminogen activator antibodies and method of use thereof |
| JP2022513626A (ja) | 2018-11-26 | 2022-02-09 | ノバルティス アーゲー | Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド |
| BR112021010047A2 (pt) | 2018-12-06 | 2021-08-24 | Bioverativ Therapeutics Inc. | Uso de vetores lentivirais expressando o fator ix |
| US20230051872A1 (en) | 2019-03-22 | 2023-02-16 | Reflexion Pharmaceuticals, Inc. | Multivalent D-Peptidic Compounds for Target Proteins |
| KR20220029545A (ko) | 2019-03-22 | 2022-03-08 | 리플렉시온 파마슈티컬스, 인크. | Vegf에 대한 d-펩티드성 화합물 |
| WO2020198731A2 (en) | 2019-03-28 | 2020-10-01 | Danisco Us Inc | Engineered antibodies |
| MX2021012250A (es) | 2019-04-11 | 2022-01-18 | Angion Biomedica Corp | Formas solidas de (e)-3-[2-(2-tienil)vinil]-1h-pirazol. |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| US12037378B2 (en) | 2019-05-21 | 2024-07-16 | Novartis Ag | Variant CD58 domains and uses thereof |
| BR112021023048A2 (pt) | 2019-05-21 | 2022-04-19 | Novartis Ag | Moléculas de ligação a cd19 e usos das mesmas |
| CN120204385A (zh) | 2019-05-24 | 2025-06-27 | 赛诺菲 | 治疗系统性硬化症的方法 |
| EP3986918A1 (en) | 2019-06-18 | 2022-04-27 | Bayer Aktiengesellschaft | Adrenomedullin-analogues for long-term stabilization and their use |
| AU2020343512A1 (en) | 2019-09-06 | 2022-04-07 | Novartis Ag | Therapeutic fusion proteins |
| US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| CN115279896A (zh) | 2019-09-30 | 2022-11-01 | 比奥维拉迪维治疗股份有限公司 | 慢病毒载体配制品 |
| JP2021066730A (ja) | 2019-10-17 | 2021-04-30 | Ｊｃｒファーマ株式会社 | 血清アルブミンと成長ホルモンの融合蛋白質の製造方法 |
| WO2021085518A1 (ja) | 2019-10-30 | 2021-05-06 | Ｊｃｒファーマ株式会社 | 血清アルブミンと成長ホルモンの融合蛋白質を含有する水性医薬組成物 |
| WO2021097376A1 (en) | 2019-11-14 | 2021-05-20 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| WO2021111143A1 (en) | 2019-12-04 | 2021-06-10 | Albumedix Limited | Methods and compositions produced thereby |
| BR112022011513A2 (pt) | 2019-12-13 | 2022-08-23 | Synthekine Inc | Ortólogos de il-2 e métodos de uso |
| US20210181200A1 (en) * | 2019-12-17 | 2021-06-17 | Women's College Hospital | Ovarian cancer biomarker and methods of using same |
| WO2021133822A1 (en) | 2019-12-24 | 2021-07-01 | Juvena Therapeutics,Inc. | Regenerative polypeptides and uses thereof |
| US20230203191A1 (en) | 2020-03-30 | 2023-06-29 | Danisco Us Inc | Engineered antibodies |
| BR112022020407A2 (pt) | 2020-04-09 | 2023-05-02 | Verve Therapeutics Inc | Edição base do pcsk9 e métodos de uso do mesmo para tratamento de doenças |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| IL299048A (en) | 2020-06-14 | 2023-02-01 | Vertex Pharma | Variants of complement factor - 1 fusion structures and preparations containing them and their uses |
| MX2023000156A (es) | 2020-06-24 | 2023-02-16 | Bioverativ Therapeutics Inc | Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina. |
| AR123862A1 (es) | 2020-10-21 | 2023-01-18 | Boehringer Ingelheim Int | Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares |
| WO2022089639A1 (zh) * | 2020-10-30 | 2022-05-05 | 深圳普罗吉医药科技有限公司 | 人血清白蛋白在治疗疾病中的应用 |
| AU2021373366A1 (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Cd19 binding molecules and uses thereof |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| CN114478800B (zh) * | 2021-02-05 | 2022-10-11 | 华南理工大学 | 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用 |
| CA3209052A1 (en) | 2021-02-19 | 2022-08-25 | Rafael Cristian CASELLAS | Single domain antibodies that neutralize sars-cov-2 |
| US12275798B2 (en) | 2021-06-17 | 2025-04-15 | Boehringer Ingelheim International Gmbh | Tri-specific binding molecules |
| EP4359425A4 (en) * | 2021-06-21 | 2025-04-09 | Juvena Therapeutics, Inc. | REGENERATIVE POLYPEPTIDES AND THEIR USES |
| CN114133458B (zh) * | 2021-12-08 | 2023-11-14 | 福州大学 | 一种在人血清白蛋白内部融合多肽的方法 |
| AR129136A1 (es) | 2022-04-26 | 2024-07-17 | Novartis Ag | Anticuerpos multiespecíficos que se dirigen a il-13 e il-18 |
| PE20250669A1 (es) | 2022-07-15 | 2025-03-04 | Boehringer Ingelheim Int | Moleculas de union para el tratamiento del cancer |
| WO2024015953A1 (en) | 2022-07-15 | 2024-01-18 | Danisco Us Inc. | Methods for producing monoclonal antibodies |
| WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| WO2024130158A1 (en) | 2022-12-16 | 2024-06-20 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease |
| CN120418282A (zh) * | 2022-12-20 | 2025-08-01 | Csl创新私人有限公司 | FcRn拮抗剂和其用途 |
| EP4389762A1 (en) | 2022-12-23 | 2024-06-26 | Ospedale San Raffaele S.r.l. | Inhibitors of dux4 activity and their use in therapy. |
| WO2024178305A1 (en) | 2023-02-24 | 2024-08-29 | Modernatx, Inc. | Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer |
| EP4442251A1 (en) | 2023-04-05 | 2024-10-09 | Albumedix Ltd | Formulations and uses thereof |
| WO2025034806A1 (en) | 2023-08-08 | 2025-02-13 | Wisconsin Alumni Research Foundation | Single-domain antibodies and variants thereof against fibroblast activation protein |
| WO2025072888A2 (en) | 2023-09-28 | 2025-04-03 | Novavax, Inc. | Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19 |
Family Cites Families (702)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5625041A (en) * | 1990-09-12 | 1997-04-29 | Delta Biotechnology Limited | Purification of proteins |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| DE2449885C3 (de) * | 1974-10-21 | 1980-04-30 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4440859A (en) * | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4363877B1 (en) | 1977-09-23 | 1998-05-26 | Univ California | Recombinant dna transfer vectors |
| US4264731A (en) * | 1977-05-27 | 1981-04-28 | The Regents Of The University Of California | DNA Joining method |
| US4283489A (en) | 1977-09-23 | 1981-08-11 | The Regents Of The University Of California | Purification of nucleotide sequences suitable for expression in bacteria |
| US4407948A (en) | 1977-09-23 | 1983-10-04 | The Regents Of The University Of California | Purification of nucleotide sequences suitable for expression in bacteria |
| US4366246A (en) | 1977-11-08 | 1982-12-28 | Genentech, Inc. | Method for microbial polypeptide expression |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| US4652525A (en) * | 1978-04-19 | 1987-03-24 | The Regents Of The University Of California | Recombinant bacterial plasmids containing the coding sequences of insulin genes |
| US4447538A (en) * | 1978-04-19 | 1984-05-08 | Regents Of The University Of California | Microorganism containing gene for human chorionic somatomammotropin |
| US5514567A (en) * | 1979-01-30 | 1996-05-07 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
| US5326859A (en) | 1979-10-30 | 1994-07-05 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
| US4342832A (en) | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
| AU538665B2 (en) | 1979-10-30 | 1984-08-23 | Juridical Foundation, Japanese Foundation For Cancer Research | Human interferon dna |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| FI86558C (fi) | 1980-01-08 | 1992-09-10 | Biogen Inc | Dna- sekvenser, rekombinant-dna- molekyler och foerfaranden foer framstaellning av humant interferon av -typ och val av dna-sekvensen. |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| FI88175C (fi) | 1980-04-03 | 1993-04-13 | Biogen Inc | Rekombinant-dna-molekyler och foerfaranden foer framstaellning av polypeptider liknande humant -interferon |
| DE3023787A1 (de) | 1980-06-25 | 1982-01-21 | Studiengesellschaft Kohle mbH, 4330 Mülheim | Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen |
| US6610830B1 (en) | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
| GR81946B (enExample) | 1980-09-25 | 1984-12-12 | Genentech Inc | |
| US4456748A (en) | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
| EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
| DE3273787D1 (en) | 1981-02-04 | 1986-11-20 | Japan Found Cancer | Human interferon-beta gene |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| NZ199722A (en) * | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| JPS57149228A (en) | 1981-03-11 | 1982-09-14 | Ajinomoto Co Inc | Novel erythropoietin and its preparation |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| CA1204682A (en) | 1981-06-19 | 1986-05-20 | Saran A. Narang | Adaptors, and synthesis and cloning of proinsulin genes |
| US4792602A (en) | 1981-06-19 | 1988-12-20 | Cornell Research Foundation, Inc. | Adaptors, and synthesis and cloning of proinsulin genes |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| IL66614A (en) | 1981-08-28 | 1985-09-29 | Genentech Inc | Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it |
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| EP0079739A3 (en) | 1981-11-12 | 1984-08-08 | The Upjohn Company | Albumin-based nucleotides, their replication and use, and plasmids for use therein |
| EP0091527A3 (en) | 1981-12-14 | 1984-07-25 | The President And Fellows Of Harvard College | Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides |
| JPS58107298A (ja) | 1981-12-21 | 1983-06-25 | Yoshitsuka Seiki:Kk | 粉末成形プレスにおけるシエ−カ−カムの位相調整装置 |
| JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
| WO1983002461A1 (en) | 1982-01-19 | 1983-07-21 | Cetus Corp | Multiclass hybrid interferons |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4450103A (en) * | 1982-03-01 | 1984-05-22 | Cetus Corporation | Process for recovering human IFN-β from a transformed microorganism |
| US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US4670393A (en) * | 1982-03-22 | 1987-06-02 | Genentech, Inc. | DNA vectors encoding a novel human growth hormone-variant protein |
| CA1341562C (en) | 1982-03-31 | 2007-11-27 | Tadatsugu Taniguchi | Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell |
| DE3377363D1 (en) | 1982-03-31 | 1988-08-18 | Ajinomoto Kk | Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells |
| US4925919A (en) * | 1984-04-25 | 1990-05-15 | Roland Mertelsmann | Purified interleukin 2 |
| US5824330A (en) | 1982-04-20 | 1998-10-20 | Sloan-Kettering Institute For Cancer Research | Highly purified interleukin-2 and method |
| US4778879A (en) | 1982-04-20 | 1988-10-18 | Sloan-Kettering Institute For Cancer Research | Highly purified human interleukin 2 and method |
| US4499188A (en) * | 1982-05-05 | 1985-02-12 | Cetus Corporation | Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| JPS5945835U (ja) | 1982-09-16 | 1984-03-27 | 株式会社東芝 | 回路しや断器の消弧装置 |
| US4490289A (en) | 1982-09-16 | 1984-12-25 | Hoffmann-La Roche Inc. | Homogeneous human interleukin 2 |
| US4992271A (en) | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
| US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
| IE56026B1 (en) | 1982-10-19 | 1991-03-27 | Cetus Corp | Cysteine-depleted muteins of biologically active proteins |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| DE3382547D1 (de) | 1983-01-12 | 1992-05-27 | Chiron Corp | Sekretorische expression in eukaryoten. |
| US4840934A (en) * | 1983-01-25 | 1989-06-20 | Eleanor Roosevelt Institute For Cancer Research, Inc. | Therapeutic method using T cell growth factor |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4914026A (en) * | 1983-04-07 | 1990-04-03 | Chiron Corporation | Alpha factor leader sequence directed secretion of insulin |
| US5015575A (en) * | 1983-04-07 | 1991-05-14 | Chiron Corporation | Hybrid DNA synthesis of insulin |
| DK172738B1 (da) | 1983-04-07 | 1999-06-21 | Chiron Corp | Fremgangsmåde til at udtrykke modent insulin og DNA-struktur til anvendelse ved fremgangsmåden |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| WO1984004330A1 (en) | 1983-04-22 | 1984-11-08 | Amgen | Secretion of exogenous polypeptides from yeast |
| NZ207926A (en) | 1983-04-25 | 1988-04-29 | Genentech Inc | Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast |
| US5010003A (en) * | 1983-04-25 | 1991-04-23 | Genentech, Inc. | Use of yeast homologous signals to secrete heterologous proteins |
| CA1196863A (en) * | 1983-06-08 | 1985-11-19 | Mattheus F.A. Goosen | Slow release injectable insulin composition |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4576813A (en) | 1983-07-05 | 1986-03-18 | Monsanto Company | Heat recovery from concentrated sulfuric acid |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| JPS6087792A (ja) | 1983-09-23 | 1985-05-17 | ジェネックス・コーポレイション | 雑種制御領域 |
| DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
| US4518564A (en) * | 1983-10-03 | 1985-05-21 | Jeneric Industries, Inc. | Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| JPS60115528A (ja) | 1983-11-28 | 1985-06-22 | Takeda Chem Ind Ltd | ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物 |
| GB8334102D0 (en) | 1983-12-21 | 1984-02-01 | Searle & Co | Interferons with cysteine pattern |
| US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
| GB8334261D0 (en) | 1983-12-22 | 1984-02-01 | Bass Plc | Fermentation processes |
| JPS60136596A (ja) | 1983-12-26 | 1985-07-20 | Suntory Ltd | ペプチド及びこれを有効成分とする利尿剤 |
| IT1185503B (it) | 1984-01-11 | 1987-11-12 | Univ New York | Cloni di odna di eritropietina umana |
| US4908433A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Uses of interleukin-2 |
| US4908434A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Process for preparing purified interleukin-2 |
| CA1213537A (en) | 1984-05-01 | 1986-11-04 | Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee | Polypeptide expression method |
| FR2564106B1 (fr) * | 1984-05-09 | 1988-04-22 | Transgene Sa | Vecteurs d'expression du facteur ix, cellules transformees par ces vecteurs et procede de preparation du facteur ix. |
| DK58285D0 (da) * | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
| EP0172619A1 (en) | 1984-06-20 | 1986-02-26 | Takeda Chemical Industries, Ltd. | Novel transformant and use thereof |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US5908763A (en) | 1984-07-06 | 1999-06-01 | Novartis Corporation | DNA encoding GM-CSF and a method of producing GM-CSF protein |
| JPS61227526A (ja) | 1984-07-25 | 1986-10-09 | Chugai Pharmaceut Co Ltd | 新規なコロニー刺激因子 |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| US4716217A (en) | 1984-08-31 | 1987-12-29 | University Patents, Inc. | Hybrid lymphoblastoid-leukocyte human interferons |
| US4734491A (en) | 1984-08-31 | 1988-03-29 | University Patents, Inc. | DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4677195A (en) | 1985-01-11 | 1987-06-30 | Genetics Institute, Inc. | Method for the purification of erythropoietin and erythropoietin compositions |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| GB8504099D0 (en) * | 1985-02-18 | 1985-03-20 | Wellcome Found | Physiologically active substances |
| DK129385A (da) | 1985-03-22 | 1986-09-23 | Novo Industri As | Peptider og fremstilling deraf |
| FR2579224B1 (fr) | 1985-03-25 | 1987-05-22 | Genetica | Procede de preparation microbiologique de la serum-albumine humaine |
| US4751180A (en) * | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| EP0196056B1 (en) | 1985-03-28 | 1991-05-22 | Chiron Corporation | Improved expression using fused genes providing for protein product |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| GB8510219D0 (en) | 1985-04-22 | 1985-05-30 | Bass Plc | Isolation of fermentation products |
| JPS6229985A (ja) | 1985-06-17 | 1987-02-07 | ジエネツクス・コ−ポレ−シヨン | クロ−ン化プレプロ−ヒト血清アルブミン遺伝子およびヒト血清アルブミン遺伝子、それらの遺伝子を含むプラスミド、プラスミドにより形質転換された微生物、およびその微生物を用いたプレプロ−ヒト血清アルブミン遺伝子の製造方法 |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5102872A (en) * | 1985-09-20 | 1992-04-07 | Cetus Corporation | Controlled-release formulations of interleukin-2 |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| JPH0618778B2 (ja) | 1985-10-04 | 1994-03-16 | 中外製薬株式会社 | 白血球減少症治療剤 |
| JPS6296086A (ja) | 1985-10-21 | 1987-05-02 | Agency Of Ind Science & Technol | 複合プラスミド |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| CA1295563C (en) | 1985-11-01 | 1992-02-11 | Robert T. Garvin | Production of active proteins containing cystine residues |
| CA1295566C (en) | 1987-07-21 | 1992-02-11 | Robert T. Garvin | Characterization and structure of genes for protease a and protease b from streptomyces griseus |
| US5641663A (en) * | 1985-11-06 | 1997-06-24 | Cangene Corporation | Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces |
| JPH0780930B2 (ja) | 1985-12-26 | 1995-08-30 | 三井石油化学工業株式会社 | α−オレフインの重合方法 |
| JPH0645551B2 (ja) | 1986-01-07 | 1994-06-15 | 塩野義製薬株式会社 | インタ−ロイキン−２組成物 |
| ATE65403T1 (de) | 1986-01-22 | 1991-08-15 | Chugai Pharmaceutical Co Ltd | Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit. |
| ATE74272T1 (de) | 1986-01-22 | 1992-04-15 | Chugai Pharmaceutical Co Ltd | Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| FR2594846B1 (fr) | 1986-02-21 | 1989-10-20 | Genetica | Procede de preparation de la serum albumine humaine mature |
| EP0237019A3 (en) | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Interferon conjugate and production thereof using recombinant gene |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IT1203758B (it) | 1986-03-27 | 1989-02-23 | Univ Roma | Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori |
| DK179286D0 (da) | 1986-04-18 | 1986-04-18 | Nordisk Gentofte | Insulinpraeparat |
| US4765980A (en) * | 1986-04-28 | 1988-08-23 | International Minerals & Chemical Corp. | Stabilized porcine growth hormone |
| US4859609A (en) | 1986-04-30 | 1989-08-22 | Genentech, Inc. | Novel receptors for efficient determination of ligands and their antagonists or agonists |
| US5028422A (en) * | 1986-05-27 | 1991-07-02 | Schering Corporation | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
| US5985599A (en) | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
| IT1204400B (it) * | 1986-06-20 | 1989-03-01 | Sclavo Spa | Composizioni farmaceutiche contenente una calcitonina |
| GB8615701D0 (en) | 1986-06-27 | 1986-08-06 | Delta Biotechnology Ltd | Stable gene integration vector |
| IT1196484B (it) | 1986-07-11 | 1988-11-16 | Sclavo Spa | Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe |
| GR871067B (en) | 1986-07-18 | 1987-11-19 | Chugai Pharmaceutical Co Ltd | Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor |
| US4857467A (en) | 1986-07-23 | 1989-08-15 | Phillips Petroleum Company | Carbon and energy source markers for transformation of strains of the genes Pichia |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5002764A (en) * | 1986-08-12 | 1991-03-26 | Schering Corporation | Treatment of actinic keratoses with alpha2 interferon |
| GB8620926D0 (en) | 1986-08-29 | 1986-10-08 | Delta Biotechnology Ltd | Yeast promoter |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4929442A (en) * | 1986-09-26 | 1990-05-29 | Exovir, Inc. | Compositions suitable for human topical application including a growth factor and/or related materials |
| US5508031A (en) * | 1986-11-21 | 1996-04-16 | Cetus Oncology Corporation | Method for treating biological damage using a free-radial scavenger and interleukin-2 |
| US4835260A (en) * | 1987-03-20 | 1989-05-30 | Genetics Institute, Inc. | Erythropoietin composition |
| FI945466A7 (fi) | 1987-03-23 | 1994-11-21 | Amgen Inc | Verihiutaleista peräisin olevaa kasvutekijää tuottavia solulinjoja |
| BR8806573A (pt) * | 1987-04-09 | 1989-10-31 | Delta Biotechnology Ltd | Vetor de levedo |
| EP0682110A1 (en) | 1987-04-22 | 1995-11-15 | Chiron Corporation | Recombinant DNA encoding PDGF A-chain polypeptides |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
| US5489425A (en) | 1987-06-24 | 1996-02-06 | The Dow Chemical Company | Functionalized polyamine chelants |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| IE62458B1 (en) | 1987-07-28 | 1995-02-08 | Gist Brocades Nv | Kluyveromyces as a host strain |
| JPH0622784Y2 (ja) | 1987-08-04 | 1994-06-15 | 東洋シヤッター株式会社 | オ−バ−ドア用可動中柱の高さ調整装置 |
| JP2627899B2 (ja) | 1987-08-19 | 1997-07-09 | 株式会社 ビタミン研究所 | 遺伝子封入リポソームの製法 |
| SE459586B (sv) | 1987-09-14 | 1989-07-17 | Mta Szegedi Biolog Koezponti | Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| JPH0811074B2 (ja) | 1987-10-30 | 1996-02-07 | 財団法人化学及血清療法研究所 | プレアルブミンをコードする遺伝子を組込んだ組換えプラスミドおよびこれを用いたプレアルブミンの製法 |
| GB8726953D0 (en) | 1987-11-18 | 1987-12-23 | Delta Biotechnology Ltd | Yeast expression system |
| JP2791418B2 (ja) * | 1987-12-02 | 1998-08-27 | 株式会社ミドリ十字 | 異種蛋白質の製造方法、組換えｄｎａ、形質転換体 |
| US5282856A (en) | 1987-12-22 | 1994-02-01 | Ledergerber Walter J | Implantable prosthetic device |
| PT89484B (pt) | 1988-01-22 | 1994-03-31 | Gen Hospital Corp | Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao |
| JPH01240191A (ja) * | 1988-02-16 | 1989-09-25 | Green Cross Corp:The | 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現 |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| US5066489A (en) | 1988-03-28 | 1991-11-19 | Cetus Corporation | Combination therapy of IL-2 and DTIC for the treatment of melanoma |
| US4999339A (en) * | 1988-03-28 | 1991-03-12 | Cetus Corporation | Combination therapy of IL-2 and DTIC for the treatment of melanoma |
| US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
| US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| US5096707A (en) * | 1988-04-15 | 1992-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers |
| US5763394A (en) * | 1988-04-15 | 1998-06-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| US5061488A (en) | 1988-04-15 | 1991-10-29 | The United States Of America As Represented Department Of Health & Human Services | Flavone-8-acetic acid and interleukin-2 for cancer therapy |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| IL89992A0 (en) | 1988-04-25 | 1989-12-15 | Phillips Petroleum Co | Expression of human serum albumin in methylotrophic yeasts |
| IL89989A0 (en) | 1988-04-25 | 1989-12-15 | Phillips Petroleum Co | Expression of human interleukin-2 in methylotrophic yeasts |
| US5126129A (en) * | 1988-05-23 | 1992-06-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Cancer therapy using interleukin-2 and flavone compounds |
| ATE101620T1 (de) | 1988-06-23 | 1994-03-15 | Hoechst Ag | Mini-proinsulin, seine herstellung und verwendung. |
| DE353450T1 (de) | 1988-06-24 | 1990-09-06 | The Dow Chemical Co., Midland, Mich. | Macrocyclische bifunktionelle chelatbildner, komplexe davon und ihre konjugierten antikoerper. |
| US5756065A (en) | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
| CN1033030C (zh) | 1988-06-24 | 1996-10-16 | 唐化学原料公司 | 大环双官能螯合剂及其配合物和抗体共轭物的制备方法 |
| US5274119A (en) | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
| DE68925893T2 (de) | 1988-07-23 | 1996-08-08 | Delta Biotechnology Ltd | Sekretorische leader-sequenzen |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| FR2635115B1 (fr) | 1988-08-05 | 1992-04-03 | Rhone Poulenc Sante | Procede de preparation de la serum albumine humaine a partir d'une levure |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| JPH04501204A (ja) | 1988-08-11 | 1992-03-05 | サイオス ノバ インコーポレイテッド | 異種タンパク発現を安定させる方法およびそれに使用するベクター |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5260202A (en) | 1988-09-07 | 1993-11-09 | Delta Biotechnology Limited | Fermentation method |
| JPH02227079A (ja) | 1988-10-06 | 1990-09-10 | Tonen Corp | ヒト血清アルブミン断片 |
| US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| US5298243A (en) | 1988-10-20 | 1994-03-29 | Denki Kagaku Kogyo Kabushiki Kaisha | Colony stimulating factor-gelatin conjugate |
| JPH02117384A (ja) | 1988-10-26 | 1990-05-01 | Tonen Corp | 酵母宿主によるヒト血清アルブミンａの製造 |
| US5759802A (en) | 1988-10-26 | 1998-06-02 | Tonen Corporation | Production of human serum alubumin A |
| ATE189526T1 (de) | 1988-10-28 | 2000-02-15 | Genentech Inc | Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten |
| US5696239A (en) | 1988-10-31 | 1997-12-09 | The Dow Chemical Company | Conjugates possessing ortho ligating functionality and complexes thereof |
| US5342604A (en) | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
| US5256410A (en) | 1988-12-01 | 1993-10-26 | Schering Corporation | Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon |
| US4975271A (en) | 1988-12-19 | 1990-12-04 | Vipont Pharmaceutical, Inc. | Muscosal delivery systems for treatment of periodontal disease |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DK105489D0 (da) * | 1989-03-03 | 1989-03-03 | Novo Nordisk As | Polypeptid |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5705363A (en) | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
| JPH04504246A (ja) | 1989-03-20 | 1992-07-30 | ザ・ジェネラル・ホスピタル・コーポレーション | インシュリン刺激ホルモン |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| DE69034168T3 (de) | 1989-03-21 | 2013-04-11 | Vical, Inc. | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5231020A (en) | 1989-03-30 | 1993-07-27 | Dna Plant Technology Corporation | Genetic engineering of novel plant phenotypes |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| DE59000270D1 (de) * | 1989-04-11 | 1992-10-01 | Boehringer Ingelheim Int | Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen. |
| FI901810A7 (fi) | 1989-04-13 | 1990-10-14 | Vascular Laboratory Inc | Puhtaan pro-urokinaasin plasminogeeniaktivaattorikompleksi, joka on sidottu ihmisen seerumialbumiiniin disulfidisillan välityksellä |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| GB8909916D0 (en) | 1989-04-29 | 1989-06-14 | Delta Biotechnology Ltd | Polypeptides |
| ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
| US5766883A (en) * | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| US5332671A (en) | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
| DK0474727T3 (da) | 1989-05-19 | 1998-01-12 | Genentech Inc | HER2 ekstracellulært domæne |
| DE69024261T2 (de) | 1989-05-24 | 1996-07-18 | Merck & Co Inc | Reinigung und Charakterisierung eines von einem Glioma abstammenden Wachstumsfaktors |
| US5808003A (en) | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
| CA2033176C (en) | 1989-06-09 | 1999-12-14 | Julian Richard Este Wells | Growth hormone fusion proteins |
| JPH0327320A (ja) | 1989-06-26 | 1991-02-05 | Ajinomoto Co Inc | ヒトｂ細胞分化因子医薬組成物 |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| DE3924746A1 (de) * | 1989-07-26 | 1991-01-31 | Behringwerke Ag | Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| CU22222A1 (es) | 1989-08-03 | 1995-01-31 | Cigb | Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes |
| GB8927480D0 (en) | 1989-12-05 | 1990-02-07 | Delta Biotechnology Ltd | Mutant fungal strain detection and new promoter |
| AU632372B2 (en) | 1989-08-22 | 1992-12-24 | Immunex Corporation | Fusion proteins comprising gm-csf and il-3 |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US6063373A (en) * | 1989-09-19 | 2000-05-16 | Maxim Pharmaceuticals, Inc. | Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| IE66494B1 (en) | 1989-09-26 | 1996-01-10 | Immunex Corp | Granulocyte-colony stimulating factor receptors |
| WO1991005052A1 (fr) | 1989-09-28 | 1991-04-18 | Leningradsky Gosudarstvenny Universitet | Procede d'obtention d'un polypeptide presentant une activite d'interleukine-2 humaine, secrete par des cellules de levure, saccharomyces cerevisiae |
| CA2067194C (en) | 1989-10-05 | 2003-03-18 | Glenn Kawasaki | Cell-free synthesis and isolation of novel genes and polypeptides |
| FR2653020B1 (fr) | 1989-10-17 | 1993-03-26 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies. |
| US5667986A (en) | 1989-10-18 | 1997-09-16 | Delta Biotechnology Limited | Yeast promoter for expressing heterologous polypeptides |
| GB8924021D0 (en) | 1989-10-25 | 1989-12-13 | Celltech Ltd | Recombinant dna method and vectors for the use therein |
| US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| DE69031305T2 (de) | 1989-11-03 | 1998-03-26 | Univ Vanderbilt | Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| US5173408A (en) | 1989-11-13 | 1992-12-22 | Lange Louis George Iii | Mammalian pancreatic cholesterol esterase |
| DK608589D0 (da) | 1989-12-01 | 1989-12-01 | Holm Arne | Kemisk fremgangsmaade |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| JPH03201987A (ja) | 1989-12-29 | 1991-09-03 | Tonen Corp | ヒト血清アルブミン断片 |
| US5116944A (en) | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| WO1991011457A1 (en) | 1990-01-24 | 1991-08-08 | Buckley Douglas I | Glp-1 analogs useful for diabetes treatment |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| EP0439442B1 (en) * | 1990-01-25 | 1996-03-06 | Washington University | Factor x-laci hybrid protein |
| JPH04211375A (ja) | 1990-02-05 | 1992-08-03 | Ajinomoto Co Inc | 合成遺伝子及びそれを用いたヒト血清アルブミンの製造法 |
| US5747334A (en) | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
| US5208018A (en) * | 1990-03-19 | 1993-05-04 | Brigham And Women's Hospital | Treatment of cachexia with interleukin 2 |
| FR2660863B1 (fr) * | 1990-04-17 | 1994-01-21 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre. |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
| GB9013017D0 (en) | 1990-06-11 | 1990-08-01 | Mars Uk Ltd | Compounds |
| US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| EP0538300B1 (de) | 1990-07-10 | 1994-04-13 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | O-glycosyliertes ifn-alpha |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5225341A (en) | 1990-07-19 | 1993-07-06 | The Regents Of The University Of California | Biologically safe plant transformation system using a ds transposon |
| US5202239A (en) * | 1990-08-07 | 1993-04-13 | Scios Nova Inc. | Expression of recombinant polypeptides with improved purification |
| US5071872A (en) | 1990-08-14 | 1991-12-10 | The Ohio State University Research Foundation | Method for improving interleukin-2 activity using aci-reductone compounds |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5391183A (en) * | 1990-09-21 | 1995-02-21 | Datascope Investment Corp | Device and method sealing puncture wounds |
| IT1242149B (it) | 1990-09-27 | 1994-02-16 | Consiglio Nazionale Ricerche | Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| AU667460B2 (en) | 1990-10-05 | 1996-03-28 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
| JPH07108232B2 (ja) | 1990-10-09 | 1995-11-22 | エム・ディ・リサーチ株式会社 | ペプチド又は蛋白質の製造方法 |
| JPH0638771Y2 (ja) | 1990-10-26 | 1994-10-12 | 株式会社カンセイ | エアバック制御装置 |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| FR2668368B1 (fr) | 1990-10-30 | 1995-03-10 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales. |
| JPH0638771A (ja) | 1990-10-31 | 1994-02-15 | Tonen Corp | ヒトプロテインジスルフィドイソメラーゼ遺伝子の発現方法および該遺伝子との共発現によるポリペプチドの製造方法 |
| US5353535A (en) | 1990-11-05 | 1994-10-11 | Plumly George W | Floor type advertising apparatus |
| US5830452A (en) | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
| ATE254179T1 (de) | 1990-11-29 | 2003-11-15 | Agronomique Inst Nat Rech | Neue type-i-interferon varianten, ihre verfahren zur herstellung, und ihre verwendungen |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5272080A (en) * | 1991-02-19 | 1993-12-21 | Pharmavene, Inc. | Production of butyrylcholinesterase |
| WO1994027631A1 (en) * | 1993-05-21 | 1994-12-08 | Zymogenetics, Inc. | Modified factor vii |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5272070A (en) * | 1991-03-08 | 1993-12-21 | Board Of Regents, The University Of Texas System | Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby |
| CA2062659A1 (en) | 1991-03-12 | 1992-09-13 | Yasutaka Igari | Composition for sustained-release of erythropoietin |
| US5817471A (en) | 1991-03-14 | 1998-10-06 | The United States Of America As Represented By The Department Of Health And Human Services | Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor |
| EP0506477B1 (en) | 1991-03-28 | 1999-06-23 | Merck & Co. Inc. | Vascular endothelial cell growth factor C subunit |
| US5374617A (en) | 1992-05-13 | 1994-12-20 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with FVIIa |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| EP0509841A3 (en) | 1991-04-18 | 1993-08-18 | Tonen Corporation | Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system |
| CA2058820C (en) | 1991-04-25 | 2003-07-15 | Kotikanyad Sreekrishna | Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells |
| US5330901A (en) | 1991-04-26 | 1994-07-19 | Research Corporation Technologies, Inc. | Expression of human serum albumin in Pichia pastoris |
| WO1992019973A1 (en) | 1991-04-26 | 1992-11-12 | Surface Active Limited | Novel antibodies, and methods for their use |
| US5646012A (en) * | 1991-04-30 | 1997-07-08 | Rhone-Poulenc Rorer S.A. | Yeast promoter and use thereof |
| FR2676070B1 (fr) | 1991-04-30 | 1994-09-30 | Rhone Poulenc Rorer Sa | Promoteur de levure et son utilisation. |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| US5304473A (en) * | 1991-06-11 | 1994-04-19 | Eli Lilly And Company | A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production |
| WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| FR2677996B1 (fr) | 1991-06-21 | 1993-08-27 | Rhone Poulenc Rorer Sa | Vecteurs de clonage et/ou d'expression preparation et utilisation. |
| US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| WO1993000109A1 (en) | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
| US5223408A (en) * | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
| JPH05292972A (ja) | 1991-07-29 | 1993-11-09 | Tonen Corp | 改良された酵母発現系 |
| EP0597010A4 (en) | 1991-07-31 | 1996-12-27 | Rhone Poulenc Rorer Int | Transgenic protein production. |
| US5723719A (en) | 1991-08-08 | 1998-03-03 | Health Research Inc. | Transgenic mouse as model for diseases involving dopaminergic dysfunction |
| DE4126968A1 (de) | 1991-08-14 | 1993-02-18 | Detlev Prof Dr Med Ganten | Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| NZ245015A (en) * | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US5679777A (en) * | 1991-11-08 | 1997-10-21 | Somatogen, Inc. | Hemoglobins as drug delivery agents |
| US5786883A (en) * | 1991-11-12 | 1998-07-28 | Pilkington Barnes Hind, Inc. | Annular mask contact lenses |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US6348327B1 (en) * | 1991-12-06 | 2002-02-19 | Genentech, Inc. | Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells |
| US5540923A (en) * | 1991-12-06 | 1996-07-30 | Landsforeningen Til Kraeftens Bekaemplse | Interferon proteins |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| DK0620849T3 (da) | 1992-01-07 | 2003-10-20 | Elan Pharm Inc | Transgene dyremodeller for Alzheimer's sygdom |
| GB9200417D0 (en) | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Cytotoxic drug therapy |
| FR2686620B1 (fr) | 1992-01-27 | 1995-06-23 | Rhone Poulenc Rorer Sa | Serum-albumine humaine, preparation et utilisation. |
| FR2686900B1 (fr) * | 1992-01-31 | 1995-07-21 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| CA2131528C (en) | 1992-03-05 | 2004-07-13 | Philip E. Thorpe | Methods and compositions for targeting the vasculature of solid tumors |
| US5230886A (en) | 1992-03-18 | 1993-07-27 | Trustees Of Boston University | Tumor cell suppression |
| DK36492D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Praeparat |
| USRE37302E1 (en) | 1992-03-19 | 2001-07-31 | Novo Nordisk A/S | Peptide |
| DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5460954A (en) | 1992-04-01 | 1995-10-24 | Cheil Foods & Chemicals, Inc. | Production of human proinsulin using a novel vector system |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| ATE182651T1 (de) | 1992-06-09 | 1999-08-15 | Hoppe Ag | Riegel und türschloss |
| JP2575298B2 (ja) | 1992-06-15 | 1997-01-22 | フアイザー・インコーポレイテツド | グルカゴン様ペプチド及びインシュリノトロピン誘導体 |
| US5686268A (en) * | 1992-06-19 | 1997-11-11 | Pfizer Inc. | Fused proteins |
| US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| JP3269504B2 (ja) | 1992-07-08 | 2002-03-25 | 三菱ウェルファーマ株式会社 | ヒト血清アルブミンの製造方法 |
| FR2694294B1 (fr) * | 1992-07-30 | 1994-09-09 | Rhone Poulenc Rorer Sa | Promoteur de levure et son utilisateur. |
| ES2153385T5 (es) | 1992-07-31 | 2008-09-01 | Genentech, Inc. | Composicion acuosa a base de hormona del crecimiento humana. |
| US5602307A (en) | 1992-08-12 | 1997-02-11 | Baylor College Of Medicine | Non-human animal having predefined allele of a cellular adhesion gene |
| DE4226971C2 (de) | 1992-08-14 | 1997-01-16 | Widmar Prof Dr Tanner | Modifizierte Pilzzellen und Verfahren zur Herstellung rekombinanter Produkte |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5731490A (en) | 1992-09-29 | 1998-03-24 | The Ontario Cancer Institute | Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1) |
| WO1994008599A1 (en) * | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
| US6221958B1 (en) * | 1993-01-06 | 2001-04-24 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5489743A (en) | 1993-01-19 | 1996-02-06 | Amgen Inc. | Transgenic animal models for thrombocytopenia |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| FR2701953B1 (fr) | 1993-02-22 | 1995-05-24 | Centre Nat Rech Scient | Protéine de fusion multi-VIP et procédé de préparation de VIP recombinant. |
| US5441734A (en) * | 1993-02-25 | 1995-08-15 | Schering Corporation | Metal-interferon-alpha crystals |
| US5780021A (en) | 1993-03-05 | 1998-07-14 | Georgetown University | Method for treating type 1 diabetes using α-interferon and/or β-i |
| US5869445A (en) | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
| US6284727B1 (en) | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
| HU225496B1 (en) | 1993-04-07 | 2007-01-29 | Scios Inc | Pharmaceutical compositions of prolonged delivery, containing peptides |
| WO1994024160A2 (en) | 1993-04-21 | 1994-10-27 | Brigham And Women's Hospital | Erythropoietin muteins with enhanced activity |
| GB9308581D0 (en) | 1993-04-26 | 1993-06-09 | Univ Manitoba | A method for induction of antigen-specific suppression of immune-response |
| JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
| US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| DK82893D0 (da) * | 1993-07-08 | 1993-07-08 | Novo Nordisk As | Peptid |
| US5512459A (en) | 1993-07-20 | 1996-04-30 | Bionebraska, Inc. | Enzymatic method for modification or recombinant polypeptides |
| EP0726772B1 (en) | 1993-08-09 | 2001-11-07 | Edward Baral | A method for sensitization of cancer cells for killer cell mediated lysis |
| ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
| AU7531094A (en) | 1993-08-24 | 1995-03-21 | Novo Nordisk A/S | Protracted glp-1 |
| GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
| US5521086A (en) * | 1993-09-16 | 1996-05-28 | Cephalon, Inc. | Secretion sequence for the production of a heterologous protein in yeast |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5459031A (en) | 1993-11-05 | 1995-10-17 | Amgen Inc. | Methods for controlling sialic acid derivatives in recombinant glycoproteins |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| CA2137206A1 (en) | 1993-12-09 | 1995-06-10 | John A. Galloway | Glucagon-like insulinotropic peptides, compositions and methods |
| AU1272295A (en) | 1993-12-17 | 1995-07-03 | Novo Nordisk A/S | Proinsulin-like compounds |
| DK144093D0 (enExample) | 1993-12-23 | 1993-12-23 | Novo Nordisk As | |
| DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
| US5550214A (en) | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5932780A (en) | 1994-02-28 | 1999-08-03 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Transgenic non-human animal assay system for anti-cholinesterase substances |
| GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
| US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
| US5652352A (en) | 1994-03-31 | 1997-07-29 | Amgen Inc. | Afamin: a human serum albumin-like gene |
| US5629286A (en) * | 1994-03-31 | 1997-05-13 | Brewitt; Barbara | Homeopathic dilutions of growth factors |
| US5646113A (en) | 1994-04-07 | 1997-07-08 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
| FR2719593B1 (fr) | 1994-05-06 | 1996-05-31 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant. |
| GB9409496D0 (en) | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
| GB9411356D0 (en) | 1994-06-07 | 1994-07-27 | Delta Biotechnology Ltd | Yeast strains |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5985660A (en) | 1994-06-15 | 1999-11-16 | Systemix, Inc. | Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation |
| US5639642A (en) * | 1994-06-16 | 1997-06-17 | Novo Nordisk A/S | Synthetic leader peptide sequences |
| US5623054A (en) | 1994-06-23 | 1997-04-22 | The General Hospital Corporation | Crucifer AFT proteins and uses thereof |
| CA2195642A1 (en) | 1994-07-27 | 1996-02-08 | Andreas Suhrbier | Polyepitope vaccines |
| JPH0851982A (ja) | 1994-08-11 | 1996-02-27 | Asahi Glass Co Ltd | ヒト血清アルブミンをコードする改変された遺伝子 |
| JPH0853500A (ja) | 1994-08-11 | 1996-02-27 | Asahi Glass Co Ltd | 融合タンパク質および該タンパク質をコードする遺伝子 |
| JPH0859509A (ja) | 1994-08-16 | 1996-03-05 | Teijin Ltd | サイトメガロウイルス抗原血症治療剤およびサイトメガロウイルス感染症治療剤 |
| US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
| US6071923A (en) * | 1994-09-16 | 2000-06-06 | Bar-Ilan University | Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases |
| US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| FR2726471B1 (fr) | 1994-11-07 | 1997-01-31 | Pf Medicament | Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins |
| FR2726576B1 (fr) | 1994-11-07 | 1997-01-31 | Pf Medicament | Production de peptides analogues de peptides hydrophobes, peptide recombinant, sequence d'adn correspondante |
| AU708972B2 (en) | 1994-11-07 | 1999-08-19 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| AT403167B (de) | 1994-11-14 | 1997-11-25 | Immuno Ag | Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems |
| US5695750A (en) | 1994-11-25 | 1997-12-09 | The United States Of America As Represented By The Secretary Of The Army | Compositions for use to deactivate organophosphates |
| AU4415796A (en) | 1994-12-07 | 1996-06-26 | Bionebraska, Inc. | Production of c-terminal amidated peptides from recombinant protein constructs |
| CA2206848A1 (en) | 1994-12-07 | 1996-06-13 | Bionebraska, Inc. | Production of peptides using recombinant fusion protein constructs |
| EP1621206A1 (en) * | 1994-12-12 | 2006-02-01 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| DE69529998D1 (de) | 1994-12-23 | 2003-04-24 | Novo Nordisk As | Glp-1 zusammensetzungen mit verlängerter wirkdauer |
| US20010006943A1 (en) | 1994-12-23 | 2001-07-05 | Ejvind Jensen | Protracted GLP-1 compositions |
| US5583415A (en) | 1994-12-27 | 1996-12-10 | Motorola, Inc. | Apparatus for simulating high battery temperature for rechargeble battery systems |
| US5652224A (en) | 1995-02-24 | 1997-07-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism |
| US5928939A (en) | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
| US5837281A (en) * | 1995-03-17 | 1998-11-17 | Takeda Chemical Industries, Ltd. | Stabilized interface for iontophoresis |
| JP2758154B2 (ja) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| JPH11507205A (ja) | 1995-04-27 | 1999-06-29 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | ヒト腫瘍壊死因子受容体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5480640A (en) | 1995-05-02 | 1996-01-02 | Schering Corporation | Alpha interferon for treating prostate cancer |
| WO1996034891A1 (en) | 1995-05-05 | 1996-11-07 | Human Genome Sciences, Inc. | Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4 |
| AU5724996A (en) | 1995-05-05 | 1996-11-21 | Eli Lilly And Company | Single chain insulin with high bioactivity |
| US5728915A (en) | 1995-05-08 | 1998-03-17 | Children's Hospital, Inc. | Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter |
| US5705151A (en) | 1995-05-18 | 1998-01-06 | National Jewish Center For Immunology & Respiratory Medicine | Gene therapy for T cell regulation |
| US6387365B1 (en) | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| US6001625A (en) | 1995-05-19 | 1999-12-14 | The United States Of America As Represented By The Secretary Of The Army | Site-directed mutagenesis of esterases |
| US5741815A (en) | 1995-06-02 | 1998-04-21 | Lai; Ching-San | Methods for in vivo reduction of nitric oxide levels and compositions useful therefor |
| US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
| US5728707A (en) * | 1995-07-21 | 1998-03-17 | Constantia Gruppe | Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5840542A (en) | 1995-07-28 | 1998-11-24 | Mogam Biotechnology Research Institute | Method for manufacture of proinsulin with high export yield |
| DE19530865A1 (de) | 1995-08-22 | 1997-02-27 | Michael Dr Med Nauck | Wirkstoff sowie Mittel zur parenteralen Ernährung |
| JPH0995455A (ja) | 1995-09-29 | 1997-04-08 | Sumitomo Pharmaceut Co Ltd | 腎機能改善剤 |
| US5766620A (en) * | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
| US5849322A (en) | 1995-10-23 | 1998-12-15 | Theratech, Inc. | Compositions and methods for buccal delivery of pharmaceutical agents |
| US5702717A (en) | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
| AU7473096A (en) | 1995-11-02 | 1997-05-22 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
| US6048964A (en) | 1995-12-12 | 2000-04-11 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
| US6080409A (en) | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
| GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| US6110707A (en) | 1996-01-19 | 2000-08-29 | Board Of Regents, The University Of Texas System | Recombinant expression of proteins from secretory cell lines |
| EP0910578A2 (en) | 1996-01-19 | 1999-04-28 | The Board Of Regents, The University Of Texas System | Recombinant expression of proteins from secretory cell lines |
| US6087129A (en) | 1996-01-19 | 2000-07-11 | Betagene, Inc. | Recombinant expression of proteins from secretory cell lines |
| US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
| US6150337A (en) | 1996-01-23 | 2000-11-21 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US5616724A (en) | 1996-02-21 | 1997-04-01 | Cephalon, Inc. | Fused pyrrolo[2,3-c]carbazole-6-ones |
| US6045788A (en) * | 1996-02-28 | 2000-04-04 | Cornell Research Foundation, Inc. | Method of stimulation of immune response with low doses of IL-2 |
| DE19639601A1 (de) | 1996-02-28 | 1997-09-04 | Bayer Ag | Parapockenviren, die Fremd-DNA enthalten, ihre Herstellung und ihre Verwendung in Impfstoffen |
| US5912229A (en) * | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
| JP4064460B2 (ja) | 1996-03-01 | 2008-03-19 | ノボ ノルディスク アクティーゼルスカブ | 食欲抑制性ペプチドを含む医薬組成物の用途 |
| JP3794748B2 (ja) * | 1996-03-04 | 2006-07-12 | 第一アスビオファーマ株式会社 | メタノール代謝系を有する微生物の培養法 |
| WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
| ATE241695T1 (de) | 1996-03-13 | 2003-06-15 | Delta Biotechnology Ltd | Gärungs-steuerungssysteme |
| JP2000506865A (ja) | 1996-03-14 | 2000-06-06 | ジ イミューン リスポンス コーポレイション | インターフェロンをコードする遺伝子の標的を定めた送達 |
| WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| WO1997034997A1 (en) | 1996-03-21 | 1997-09-25 | Human Genome Sciences, Inc. | Human endometrial specific steroid-binding factor i, ii and iii |
| EP0904278A4 (en) | 1996-03-22 | 1999-09-15 | Human Genome Sciences Inc | MOLECULE II INDUCER OF APOPTOSIS |
| US6204022B1 (en) * | 1996-04-12 | 2001-03-20 | Pepgen Corporation And University Of Florida | Low-toxicity human interferon-alpha analogs |
| AU2667197A (en) | 1996-04-16 | 1997-11-07 | University Of Miami | Stabilized preparations of human troponins and modifications thereof, diagnostic assay methods and assay kits |
| WO1997039775A1 (en) * | 1996-04-23 | 1997-10-30 | Chugai Seiyaku Kabushiki Kaisha | Cerebral stroke/cerebral edema preventive or remedy containing il-8 binding inhibitor as active ingredient |
| CA2255615C (en) * | 1996-05-22 | 2006-08-29 | Neuromedica, Inc. | Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel |
| US5919815A (en) | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
| US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| EP0917566B1 (de) * | 1996-06-11 | 2004-09-22 | Roche Diagnostics GmbH | Rekombinante blutgerinnungsproteasen |
| US6110891A (en) | 1996-06-21 | 2000-08-29 | Alizyme Therapeutics Ltd. | Lectin compositions and uses thereof |
| GB2318352A (en) | 1996-06-25 | 1998-04-22 | Dejan Markovic | Polypeptides mimicking the activity of human erythropoietin |
| GB9613858D0 (en) | 1996-07-02 | 1996-09-04 | Cortecs Ltd | Hydrophobic preparations |
| US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
| US6110703A (en) | 1996-07-05 | 2000-08-29 | Novo Nordisk A/S | Method for the production of polypeptides |
| ATE294863T1 (de) | 1996-07-15 | 2005-05-15 | Chugai Pharmaceutical Co Ltd | Neuartige vegf-ähnliche faktoren |
| AR008077A1 (es) | 1996-07-26 | 1999-12-09 | Talarico Salinas Laura Beatriz | Un polipeptido de fusion o una sal del mismo, su uso, un proceso para prepararlos, una composicion farmaceutica que los comprende, y un vector. |
| WO1998005782A1 (en) | 1996-08-02 | 1998-02-12 | Zymogenetics, Inc. | Testis-specific insulin homolog polypeptides |
| US6190533B1 (en) | 1996-08-15 | 2001-02-20 | Exxon Chemical Patents Inc. | Integrated hydrotreating steam cracking process for the production of olefins |
| ES2316153T3 (es) | 1996-08-16 | 2009-04-01 | Human Genome Sciences, Inc. | Endoquina alfa humana. |
| WO1998006842A1 (en) | 1996-08-16 | 1998-02-19 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| EP1749836B1 (en) | 1996-08-23 | 2009-06-17 | Vegenics Limited | Recombinant vascular endothelial cell growth factor D (VEGF-D) |
| US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US5922761A (en) | 1996-09-06 | 1999-07-13 | Medinox, Inc. | Methods for in vivo reduction of iron levels and compositions useful therefor |
| WO1998011136A1 (en) | 1996-09-09 | 1998-03-19 | Novo Nordisk A/S | A cDNA AND PEPTIDE WITH RELATION TO CANCER AND WEIGHT LOSS |
| US20020052309A1 (en) | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
| EP0961832A4 (en) * | 1996-09-18 | 2003-02-26 | Human Genome Sciences Inc | HUMAN TUMOR NECROSIS FACTOR-TYPE RECEPTOR GENES |
| US6225290B1 (en) | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
| US5994112A (en) | 1996-10-09 | 1999-11-30 | Incyte Pharmaceuticals, Inc. | Human protein tyrosine kinase |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US5955508A (en) * | 1996-10-15 | 1999-09-21 | Loyola University Of Chicago | Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens |
| JP2001504326A (ja) | 1996-10-18 | 2001-04-03 | ジェネンテック インコーポレーテッド | 抗ＥｒｂＢ２抗体 |
| AU4988697A (en) | 1996-10-24 | 1998-05-15 | Vion Pharmaceuticals, Inc. | Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents |
| BR9612752A (pt) | 1996-10-25 | 2000-01-18 | Human Genome Sciences Inc | Neutrocina |
| JPH10134761A (ja) | 1996-10-30 | 1998-05-22 | Ebara Corp | イオン注入装置及びイオン注入方法 |
| US5908830A (en) * | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
| EP1306092A3 (en) | 1996-11-05 | 2003-05-07 | Eli Lilly & Company | Use of GLP-1 and analogs administered peripherally, in regulation of obesity |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| GB9623205D0 (en) * | 1996-11-07 | 1997-01-08 | Eurand Int | Novel pharmaceutical compositions |
| EP0941114B1 (en) | 1996-11-12 | 2005-02-23 | Novo Nordisk A/S | Use of glp-1 peptides |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6130248A (en) | 1996-12-30 | 2000-10-10 | Bar-Ilan University | Tricarboxylic acid-containing oxyalkyl esters and uses thereof |
| US5833994A (en) | 1997-01-08 | 1998-11-10 | Paracelsian, Inc. | Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection |
| ATE321855T1 (de) | 1997-01-14 | 2006-04-15 | Human Genome Sciences Inc | Tumor-nekrose-faktor rezeptor 5 |
| JP2001527387A (ja) | 1997-01-24 | 2001-12-25 | ノボ ノルディスク アクティーゼルスカブ | 合成リーダーペプチド配列 |
| ATE362982T1 (de) | 1997-01-28 | 2007-06-15 | Human Genome Sciences Inc | ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET |
| EP0921817B1 (en) | 1997-01-29 | 2001-03-28 | PolyMASC Pharmaceuticals plc | Pegylation process |
| AU746826B2 (en) | 1997-02-13 | 2002-05-02 | Regents Of The University Of California, The | Production of mature proteins in plants |
| GB2324529A (en) | 1997-02-21 | 1998-10-28 | Merck & Co Inc | A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases |
| US7026447B2 (en) * | 1997-10-09 | 2006-04-11 | Human Genome Sciences, Inc. | 53 human secreted proteins |
| US6124495A (en) | 1997-03-11 | 2000-09-26 | Beacon Laboratories, Inc. | Unsaturated oxyalkylene esters and uses thereof |
| US6030961A (en) * | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
| US5939455A (en) | 1997-03-11 | 1999-08-17 | Beacon Laboratories, Inc. | Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives |
| US6110955A (en) | 1997-03-11 | 2000-08-29 | Beacon Laboratories, Inc. | Metabolically stabilized oxyalkylene esters and uses thereof |
| US6110970A (en) | 1997-03-11 | 2000-08-29 | Beacon Laboratories, Inc. | Nitrogen-containing oxyalkylene esters and uses thereof |
| US5846774A (en) | 1997-03-21 | 1998-12-08 | Bionebraska, Inc. | Chlorella virus promoters |
| US5981488A (en) | 1997-03-31 | 1999-11-09 | Eli Lillly And Company | Glucagon-like peptide-1 analogs |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| TW577759B (en) | 1997-04-18 | 2004-03-01 | Ipsen Pharma Biotech | Sustained release compositions in the form of microcapsules or implants and the process for their preparation |
| WO1998050347A1 (en) | 1997-05-05 | 1998-11-12 | The Regents Of The University Of California | Naphthols useful in antiviral methods |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1998054202A1 (en) | 1997-05-30 | 1998-12-03 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor tr10 |
| US6071743A (en) | 1997-06-02 | 2000-06-06 | Subsidiary No. 3, Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| WO1998056892A1 (en) | 1997-06-11 | 1998-12-17 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor tr9 |
| GB9713412D0 (en) | 1997-06-26 | 1997-08-27 | Delta Biotechnology Ltd | Improved protein expression strains |
| US5858719A (en) | 1997-07-17 | 1999-01-12 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding human ATP binding-cassette transport protein and methods of use |
| PT902085E (pt) | 1997-09-01 | 2004-02-27 | Aventis Pharma Gmbh | Eritropoietina humana recombinante com perfil de glicosilacao vantajoso |
| HUP9701554D0 (en) | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
| US6472373B1 (en) | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
| ATE230999T1 (de) | 1997-09-21 | 2003-02-15 | Schering Corp | Kombinationstherapie zur entfernung von nachweisbarer hcv-rns in patienten mit chronischer hepatitis c-infection |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| CA2304808C (en) | 1997-09-23 | 2011-03-22 | Michael Tschope | Liquid interferon-.beta. formulations |
| US6004573A (en) | 1997-10-03 | 1999-12-21 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| US6201072B1 (en) * | 1997-10-03 | 2001-03-13 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| US6117949A (en) | 1998-10-01 | 2000-09-12 | Macromed, Inc. | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| EP1042342A4 (en) * | 1997-10-09 | 2003-04-09 | Human Genome Sciences Inc | 53 PROTEINS OF HUMAN ORIGIN |
| ES2303358T3 (es) | 1997-11-03 | 2008-08-01 | Human Genome Sciences, Inc. | Vegi, un inhibidor de la angiogenesis y el crecimiento tumoral. |
| KR100390325B1 (ko) | 1997-12-03 | 2003-07-07 | 로셰 디아그노스틱스 게엠베하 | 높은 특이활성을 가진 에리트로포이에틴 |
| AU1617399A (en) | 1997-12-05 | 1999-06-28 | Eli Lilly And Company | Glp-1 formulations |
| ES2216335T3 (es) * | 1997-12-08 | 2004-10-16 | Bristol-Myers Squibb Company | Nuevas sales de metformina y procedimiento. |
| ES2590912T3 (es) | 1997-12-08 | 2016-11-24 | Merck Patent Gmbh | Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario |
| US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
| KR100253916B1 (ko) | 1997-12-29 | 2000-05-01 | 김충환 | 사람 인슐린 전구체의 제조방법 |
| US5951996A (en) | 1998-02-04 | 1999-09-14 | Czeizler Zaharia; Veronica L. | Treatment of chronic diffuse GI bleeding with erythropoietin |
| US6221378B1 (en) * | 1998-02-10 | 2001-04-24 | Generex Pharmaceuticals Incorporated | Mixed micellar delivery system and method of preparation |
| US6017545A (en) * | 1998-02-10 | 2000-01-25 | Modi; Pankaj | Mixed micellar delivery system and method of preparation |
| CA2320371C (en) | 1998-02-13 | 2012-01-17 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and glp-1 |
| ATE466027T1 (de) | 1998-02-27 | 2010-05-15 | Novo Nordisk As | Abkömmlinge von glp-1 analogen |
| WO1999047160A1 (en) | 1998-03-13 | 1999-09-23 | Novo Nordisk A/S | Stabilized aqueous peptide solutions |
| AU3087599A (en) | 1998-03-19 | 1999-10-11 | Bionebraska, Inc. | Human appetite control by glucagon-like peptide receptor binding compounds |
| DE19813802A1 (de) | 1998-03-27 | 1999-11-11 | Retro Tech Gmbh | Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen |
| GB9806631D0 (en) | 1998-03-28 | 1998-05-27 | Safeglass Europ Limited | Safetyglass |
| WO1999053064A2 (en) | 1998-04-13 | 1999-10-21 | Modex Therapeutiques, S.A. | Methods of delivering glp-1 |
| CA2270320A1 (en) | 1998-04-28 | 1999-10-28 | Patricia Lee Brubaker | Novel microsphere composition |
| US6251868B1 (en) | 1998-04-30 | 2001-06-26 | Teijin Limited | Method for treating a human immunodeficiency virus infection |
| CN1119352C (zh) | 1998-05-15 | 2003-08-27 | 中国科学院上海生物化学研究所 | 人血清白蛋白在毕赤酵母中的表达与纯化 |
| BR9910505A (pt) | 1998-05-15 | 2001-01-02 | Schering Corp | Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c |
| US5970300A (en) * | 1998-06-01 | 1999-10-19 | Xerox Corporation | Apparatus for applying scents to paper in a printer/copier |
| SE9802080D0 (sv) | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
| EP1083924B1 (en) | 1998-06-12 | 2004-07-14 | Amylin Pharmaceuticals, Inc. | Glucagon-like peptide-1 (glp-1) improves beta-cell response to glucose in subjects with impaired glucose tolerance |
| AU775422B2 (en) * | 1998-06-15 | 2004-07-29 | Gtc Biotherapeutics, Inc. | Erythropoietin analog-human serum albumin fusion |
| CN1105727C (zh) | 1998-06-17 | 2003-04-16 | 上海海济医药生物工程有限公司 | 重组人血清白蛋白的生产方法 |
| AU4716299A (en) | 1998-06-24 | 2000-01-10 | Emory University | Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv |
| CA2336112A1 (en) | 1998-06-30 | 2000-01-13 | Flemming Manique | Seeding crystals for the preparation of peptides or proteins |
| AU8508398A (en) | 1998-07-15 | 2000-02-07 | Wisconsin Alumni Research Foundation | Treatment of diabetes with synthetic beta cells |
| JP2002523333A (ja) | 1998-07-31 | 2002-07-30 | ノボ ノルディスク アクティーゼルスカブ | Ｉｉ型糖尿病を予防するためのｇｌｐ−１及び類似体の利用 |
| GB9817084D0 (en) | 1998-08-06 | 1998-10-07 | Wood Christopher B | A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders |
| ES2553108T3 (es) | 1998-08-10 | 2015-12-04 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diferenciación de células no productoras de insulina en células productoras de insulina mediante GLP-1 o exendina-4 y utilizaciones de las mismas |
| US6346543B1 (en) * | 1998-08-17 | 2002-02-12 | Aventis Pharma S.A. | Use of a taxoid to treat abnormal cell proliferation in the brain |
| EA200100289A1 (ru) | 1998-08-28 | 2001-10-22 | Эли Лилли Энд Компани | Способ введения инсулинотропных пептидов |
| MY155270A (en) | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
| US6290987B1 (en) | 1998-09-27 | 2001-09-18 | Generex Pharmaceuticals, Inc. | Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids |
| US6193997B1 (en) * | 1998-09-27 | 2001-02-27 | Generex Pharmaceuticals Inc. | Proteinic drug delivery system using membrane mimetics |
| US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
| US6429197B1 (en) | 1998-10-08 | 2002-08-06 | Bionebraska, Inc. | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
| JP2002527096A (ja) | 1998-10-16 | 2002-08-27 | イミュネックス・コーポレーション | 血小板の活性化及び補充の阻害剤 |
| JP4809977B2 (ja) | 1998-10-23 | 2011-11-09 | アムジエン・インコーポレーテツド | 貧血の予防および治療用の方法および組成物 |
| ATE365210T1 (de) | 1998-10-30 | 2007-07-15 | Novozymes As | Glykosylierte proteine mit reduzierter allergenität |
| WO2000032772A2 (en) | 1998-11-30 | 2000-06-08 | Eli Lilly And Company | Erythropoietic compounds |
| US6048891A (en) * | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
| US6294153B1 (en) | 1998-12-21 | 2001-09-25 | Generex Pharmaceuticals, Inc. | Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
| US6312665B1 (en) | 1998-12-21 | 2001-11-06 | Generex Pharmaceuticals Incorporated | Aerosol formulations for buccal and pulmonary application |
| US6271200B1 (en) | 1998-12-21 | 2001-08-07 | Generex Pharmaceuticals Inc. | Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles |
| ATE307603T1 (de) | 1998-12-22 | 2005-11-15 | Lilly Co Eli | Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1 |
| GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
| US7109292B2 (en) * | 1999-03-08 | 2006-09-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU4451300A (en) | 1999-04-09 | 2000-11-14 | Human Genome Sciences, Inc. | 48 human secreted proteins |
| WO2000062759A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Dry, mouldable drug formulation |
| US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
| US6348192B1 (en) * | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
| DE19921537A1 (de) | 1999-05-11 | 2000-11-23 | Dieter Hoersch | Verfahren zur Induzierung von Zellwachstum durch Verwendung geeigneter Mittel |
| US6329336B1 (en) | 1999-05-17 | 2001-12-11 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
| US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
| ATE369384T1 (de) | 1999-05-19 | 2007-08-15 | Emd Lexigen Res Ct Corp | Expression und export von interferon-alpha proteinen als fc fusionsproteine |
| US6344180B1 (en) | 1999-06-15 | 2002-02-05 | Bionebraska, Inc. | GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes |
| DE60036367T2 (de) | 1999-06-21 | 2008-05-29 | Eli Lilly And Co., Indianapolis | Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes |
| JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| IL147714A0 (en) | 1999-07-19 | 2002-08-14 | Gpc Biotech Inc | Chimeric polypeptides of serum albumin and uses related thereto |
| US20020048571A1 (en) | 1999-07-19 | 2002-04-25 | Jeno Gyuris | Chimeric polypeptides of serum albumin and uses related thereto |
| CA2382148A1 (en) | 1999-08-17 | 2001-02-22 | Human Genome Sciences, Inc. | 25 human secreted proteins |
| US7144574B2 (en) * | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
| TW200514783A (en) | 1999-09-22 | 2005-05-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| WO2001029242A2 (en) | 1999-10-21 | 2001-04-26 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
| AU1226901A (en) | 1999-10-22 | 2001-05-08 | Amgen, Inc. | Biodegradable microparticles with novel erythropoietin stimulating protein |
| WO2001032200A1 (en) | 1999-11-03 | 2001-05-10 | Novo Nordisk A/S | Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety |
| CA2324801A1 (en) | 1999-11-10 | 2001-05-10 | Andrew Gordon Swick | Use of apo b secretion/mtp inhibitors and anti-obesity agents |
| US6569832B1 (en) * | 1999-11-12 | 2003-05-27 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| EP1257282A4 (en) | 1999-12-06 | 2003-05-02 | Gen Hospital Corp | PANCREATIC STEM CELLS AND THEIR USE IN TRANSPLANTATION |
| US20020025306A1 (en) | 2000-01-07 | 2002-02-28 | Baetge Edward E. | Methods of increasing the glucose responsiveness of pancreatic ss-cells |
| EP1125579A3 (en) | 2000-01-18 | 2003-01-02 | Pfizer Products Inc. | Uses of agrp-melanocortin receptor binding modulating compounds |
| WO2001055213A2 (en) | 2000-01-27 | 2001-08-02 | Eli Lilly And Company | Process for solubilizing glucagon-like peptide 1 (glp-1) compounds |
| WO2001057084A1 (en) | 2000-01-31 | 2001-08-09 | Novo Nordisk A/S | Crystallisation of a glp-1 analogue |
| WO2001068112A2 (en) | 2000-03-14 | 2001-09-20 | Goeke Burkhard | Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility |
| CA2405550A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050100991A1 (en) | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2001255516B2 (en) | 2000-04-21 | 2007-01-18 | Amgen Inc. | Methods and compositions for the prevention and treatment of anemia |
| IL142707A0 (en) | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
| CZ304855B6 (cs) * | 2000-05-15 | 2014-12-10 | F. Hoffmann-La Roche Ag | Kapalná farmaceutická kompozice obsahující pegylovaný lidský erythropoetin, způsob její přípravy, léčivo pro léčení chorob korelujících s anemií při chronickém renálním selhání a zařízení s jejím obsahem |
| US20020061838A1 (en) | 2000-05-17 | 2002-05-23 | Barton Holmquist | Peptide pharmaceutical formulations |
| BR0111562A (pt) | 2000-06-16 | 2003-04-15 | Lilly Co Eli | Análogos de peptìdeo 1 semelhantes ao glucagon |
| ATE396738T1 (de) | 2000-09-18 | 2008-06-15 | Sanos Bioscience As | Verwendung von glp-2-peptiden |
| US7101561B2 (en) * | 2000-12-01 | 2006-09-05 | Innogenetics N.V. | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
| AU2002221222A1 (en) | 2000-12-04 | 2002-06-18 | Biovitrum Ab | Novel method and use |
| DK1355942T3 (da) | 2000-12-07 | 2008-11-17 | Lilly Co Eli | GLP-1-fusionsproteiner |
| WO2002048192A2 (en) | 2000-12-13 | 2002-06-20 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
| US7259233B2 (en) | 2000-12-13 | 2007-08-21 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
| US7070973B2 (en) | 2000-12-26 | 2006-07-04 | Board Of Regents Of The University Of Nebraska | Butyrylcholinesterase variants and methods of use |
| WO2002066062A2 (en) | 2001-02-01 | 2002-08-29 | Drucker Daniel J | Enhancement of glp-2 activity |
| KR100399337B1 (ko) | 2001-02-07 | 2003-09-26 | 드림바이오젠 주식회사 | 단백질의 무세포 번역후수식법 |
| EP1949908A1 (en) | 2001-03-07 | 2008-07-30 | Novo Nordisk A/S | Combined use of derivatives of GLP-1 analogs and PPAR ligands |
| US20020169128A1 (en) | 2001-04-09 | 2002-11-14 | Geroge Sigounas | Erythropoietin ameliorates chemotherapy-induced toxicity in vivo |
| US20050054051A1 (en) | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20060084794A1 (en) * | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050244931A1 (en) | 2001-04-12 | 2005-11-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2002085406A1 (en) | 2001-04-24 | 2002-10-31 | Restoragen, Inc. | Methods and compositions for treating conditions associated with insulin resistance |
| AU2002310122A1 (en) | 2001-05-25 | 2002-12-09 | Human Genome Sciences, Inc. | Chemokine beta-1 fusion proteins |
| EP1542712A2 (en) | 2001-06-01 | 2005-06-22 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
| ES2275889T3 (es) | 2001-06-20 | 2007-06-16 | Merck Sante | Utilizacion de agentes antidiabeticos para fabricar un medicamento que tiene un efecto cicatrizante. |
| DK1412384T3 (da) | 2001-06-28 | 2008-04-28 | Novo Nordisk As | Stabil formulering af modificeret GLP-1 |
| ATE408414T1 (de) | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
| AU2002327430A1 (en) | 2001-08-08 | 2003-02-24 | Genzyme Corporation | Methods for treating diabetes and other blood sugar disorders |
| EP1423136A4 (en) | 2001-08-10 | 2007-07-25 | Epix Pharm Inc | POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES |
| US7101843B2 (en) | 2001-08-23 | 2006-09-05 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
| WO2003030821A2 (en) | 2001-10-05 | 2003-04-17 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ES2561985T3 (es) | 2001-10-10 | 2016-03-01 | Ratiopharm Gmbh | Remodelación y glicoconjugación de anticuerpos |
| KR101271635B1 (ko) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2002364586A1 (en) * | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| AU2002353374A1 (en) | 2001-12-21 | 2003-07-09 | Nexia Biotechnologies, Inc. | Production of butyrylcholinesterases in transgenic mammals |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| US20080167238A1 (en) * | 2001-12-21 | 2008-07-10 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| MXPA04012496A (es) * | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Glicoformos del factor vii pegilados. |
| CN1241946C (zh) * | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
| US6913890B2 (en) * | 2002-12-18 | 2005-07-05 | Palo Alto Research Center Incorporated | Process for preparing albumin protein conjugated oligonucleotide probes |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US8986607B2 (en) * | 2003-02-27 | 2015-03-24 | Baxter International Inc. | Method for the validatable inactivation of pathogens in a biological fluid by irradiation |
| CA2528591C (en) | 2003-06-12 | 2013-01-08 | Eli Lilly And Company | Glp-1 analog fusion proteins |
| SI1729795T1 (sl) | 2004-02-09 | 2016-04-29 | Human Genome Sciences, Inc. | Albuminski fuzijski proteini |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
| US7436410B2 (en) * | 2005-04-01 | 2008-10-14 | Seiko Epson Corporation | System and method for programming a controller |
| KR20080071119A (ko) | 2005-08-12 | 2008-08-01 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| US7438904B1 (en) | 2005-10-04 | 2008-10-21 | University Of Kentucky Research Foundation | High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same |
| US8008257B2 (en) | 2005-10-20 | 2011-08-30 | University Of Ottawa Heart Institute | ANF fusion proteins |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| EP2046367A4 (en) | 2006-06-07 | 2009-11-11 | Human Genome Sciences Inc | ALBUM INFUSION PROTEINS |
| DK2717898T3 (en) * | 2011-06-10 | 2019-03-25 | Bioverativ Therapeutics Inc | COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF |
-
2001
- 2001-04-12 CA CA002405550A patent/CA2405550A1/en not_active Abandoned
- 2001-04-12 EP EP10075387A patent/EP2267026A1/en not_active Withdrawn
- 2001-04-12 WO PCT/US2001/011991 patent/WO2001079480A1/en not_active Ceased
- 2001-04-12 JP JP2001577426A patent/JP2003531590A/ja active Pending
- 2001-04-12 JP JP2001576866A patent/JP2003530839A/ja active Pending
- 2001-04-12 EP EP01941457A patent/EP1278544A4/en not_active Ceased
- 2001-04-12 DK DK10075010.8T patent/DK2236152T3/da active
- 2001-04-12 US US09/833,245 patent/US20040010134A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011988 patent/WO2001077137A1/en not_active Ceased
- 2001-04-12 DK DK10075011.6T patent/DK2216409T3/en active
- 2001-04-12 EP EP10075375A patent/EP2298355A3/en not_active Withdrawn
- 2001-04-12 WO PCT/US2001/012008 patent/WO2001079258A1/en not_active Ceased
- 2001-04-12 AU AU2001262942A patent/AU2001262942A1/en not_active Abandoned
- 2001-04-12 AU AU2001274809A patent/AU2001274809A1/en not_active Abandoned
- 2001-04-12 EP EP01932546A patent/EP1274719A4/en not_active Ceased
- 2001-04-12 EP EP01938994A patent/EP1276849A4/en not_active Withdrawn
- 2001-04-12 CA CA002405525A patent/CA2405525A1/en not_active Abandoned
- 2001-04-12 CA CA002405701A patent/CA2405701A1/en not_active Withdrawn
- 2001-04-12 AU AU2001259063A patent/AU2001259063A1/en not_active Abandoned
- 2001-04-12 EP EP10075499A patent/EP2357008A1/en not_active Withdrawn
- 2001-04-12 EP EP10075388A patent/EP2311872A1/en not_active Withdrawn
- 2001-04-12 US US09/833,041 patent/US6994857B2/en not_active Expired - Lifetime
- 2001-04-12 EP EP08075327A patent/EP1983055A1/en not_active Withdrawn
- 2001-04-12 JP JP2001576855A patent/JP2003530838A/ja active Pending
- 2001-04-12 WO PCT/US2001/011850 patent/WO2001079442A2/en not_active Ceased
- 2001-04-12 AU AU2001261024A patent/AU2001261024A1/en not_active Abandoned
- 2001-04-12 EP EP01934875A patent/EP1278767A4/en not_active Withdrawn
- 2001-04-12 EP EP01932549A patent/EP1274720A4/en not_active Ceased
- 2001-04-12 CA CA002405709A patent/CA2405709A1/en not_active Abandoned
- 2001-04-12 EP EP06015131A patent/EP1803730A1/en not_active Withdrawn
- 2001-04-12 EP EP10075164A patent/EP2213743A1/en not_active Withdrawn
- 2001-04-12 WO PCT/US2001/012009 patent/WO2001079271A1/en not_active Ceased
- 2001-04-12 EP EP06076852A patent/EP1832599A3/en not_active Ceased
- 2001-04-12 CA CA2405557A patent/CA2405557C/en not_active Expired - Lifetime
- 2001-04-12 EP EP10075391A patent/EP2295456A1/en not_active Ceased
- 2001-04-12 US US09/833,117 patent/US20030171267A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011924 patent/WO2001079443A2/en not_active Ceased
- 2001-04-12 EP EP10075064A patent/EP2206720A1/en not_active Withdrawn
- 2001-04-12 EP EP10075010.8A patent/EP2236152B1/en not_active Expired - Lifetime
- 2001-04-12 WO PCT/US2001/012013 patent/WO2001079444A2/en not_active Ceased
- 2001-04-12 ES ES10075011.6T patent/ES2529300T3/es not_active Expired - Lifetime
- 2001-04-12 JP JP2001577463A patent/JP2003530852A/ja active Pending
- 2001-04-12 AU AU2001259066A patent/AU2001259066A1/en not_active Abandoned
- 2001-04-12 EP EP01937179A patent/EP1276856A4/en not_active Withdrawn
- 2001-04-12 AU AU2001264563A patent/AU2001264563A1/en not_active Abandoned
- 2001-04-12 ES ES10075010.8T patent/ES2484966T3/es not_active Expired - Lifetime
- 2001-04-12 US US09/832,929 patent/US6926898B2/en not_active Expired - Lifetime
- 2001-04-12 JP JP2001575607A patent/JP2004506407A/ja active Pending
- 2001-04-12 EP EP10075316A patent/EP2275557A1/en not_active Withdrawn
- 2001-04-12 JP JP2001577427A patent/JP2003530846A/ja active Pending
- 2001-04-12 JP JP2001577428A patent/JP2003530847A/ja active Pending
- 2001-04-12 US US09/833,118 patent/US6905688B2/en not_active Expired - Lifetime
- 2001-04-12 EP EP08075909A patent/EP2067488A1/en not_active Withdrawn
- 2001-04-12 CA CA002405563A patent/CA2405563A1/en not_active Abandoned
- 2001-04-12 EP EP10075011.6A patent/EP2216409B1/en not_active Expired - Lifetime
- 2001-04-12 CA CA2747325A patent/CA2747325A1/en not_active Abandoned
- 2001-04-12 AU AU2001266557A patent/AU2001266557A1/en not_active Abandoned
- 2001-04-12 EP EP01944114A patent/EP1276756A4/en not_active Withdrawn
- 2001-04-12 US US09/832,501 patent/US20030199043A1/en not_active Abandoned
- 2001-04-12 CA CA002405912A patent/CA2405912A1/en not_active Abandoned
-
2005
- 2005-03-14 US US11/078,663 patent/US7507414B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/078,914 patent/US7482013B2/en not_active Expired - Lifetime
-
2007
- 2007-10-29 US US11/927,610 patent/US20080269127A1/en not_active Abandoned
- 2007-10-29 US US11/927,602 patent/US10080785B2/en not_active Expired - Lifetime
- 2007-10-29 US US11/927,555 patent/US20090285816A9/en not_active Abandoned
- 2007-10-29 US US11/927,593 patent/US20080261877A1/en not_active Abandoned
- 2007-10-29 US US11/927,617 patent/US20080269128A1/en not_active Abandoned
- 2007-10-29 US US11/927,607 patent/US20080269126A1/en not_active Abandoned
- 2007-10-29 US US11/927,600 patent/US9821039B2/en not_active Expired - Fee Related
- 2007-10-29 US US11/927,583 patent/US20120141415A1/en not_active Abandoned
- 2007-10-30 US US11/929,677 patent/US7785599B2/en not_active Expired - Fee Related
-
2009
- 2009-02-04 US US12/365,878 patent/US20110280830A9/en not_active Abandoned
-
2011
- 2011-05-16 JP JP2011109620A patent/JP2011217750A/ja active Pending
- 2011-08-18 US US13/212,879 patent/US20120252732A1/en not_active Abandoned
-
2012
- 2012-05-04 US US13/464,248 patent/US8946156B2/en not_active Expired - Fee Related
-
2013
- 2013-04-02 US US13/855,434 patent/US9775888B2/en not_active Expired - Fee Related
- 2013-04-02 US US13/855,454 patent/US9849162B2/en not_active Expired - Fee Related
- 2013-10-17 JP JP2013216509A patent/JP2014057589A/ja active Pending
-
2016
- 2016-11-04 FR FR16C0043C patent/FR16C0043I2/fr active Active
- 2016-11-04 BE BE2016C059C patent/BE2016C059I2/nl unknown
-
2017
- 2017-12-21 US US15/850,371 patent/US20180200346A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003530839A5 (enExample) | ||
| CA1340641C (en) | Recombinant lymphotoxin | |
| JP5753692B2 (ja) | タンパク質製剤 | |
| CN103118699B (zh) | 白介素-22在治疗病毒性肝炎中的应用 | |
| JP2005538932A5 (enExample) | ||
| JP2001520238A5 (enExample) | ||
| WO1996035789A1 (en) | Human interferon tau compositions and methods of use | |
| RU2000133344A (ru) | Улучшенный способ получения аддуктов аминов с о-гидроксиальдегидами, являющихся основаниями шиффа, и композиции веществ на их основе | |
| HRP20170755T1 (hr) | Rekombinantni proteini elastaze i postupci proizvodnje i uporabe istih | |
| RU2005113692A (ru) | Вакцина против hcv | |
| CA2311648A1 (en) | Ifnar2/ifn complex | |
| WO2004048402B1 (en) | A hepatitis c virus codon optimized non-structural ns3/4a fusion gene | |
| US7232563B2 (en) | Hybrid interferon/interferon tau proteins, compositions and methods of use | |
| Pontzer et al. | Structure/function studies with interferon tau: evidence for multiple active sites | |
| JP2005525784A5 (enExample) | ||
| GR3024679T3 (en) | Mutants of human interleukin-3 | |
| JP2002518011A5 (enExample) | ||
| CN101463089B (zh) | 人血清白蛋白-干扰素融合蛋白及其编码基因与应用 | |
| US5824509A (en) | Recombinant lymphotoxin cDNA and variants | |
| NZ264218A (en) | Storage stable aqueous composition of alpha-interferon | |
| CA2272051A1 (en) | Bovine lactation associated immunotropic protein (cd14), encoding gene and application in b cell activation | |
| EP0367575B1 (en) | Human lymphotoxin | |
| JPH09157294A (ja) | 副甲状腺ホルモン誘導体 | |
| JP2002522021A5 (enExample) | ||
| LT6164B (lt) | Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas |